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ABSTRACT 
Vascular smooth muscle cells (SMCs) regulate vessel contraction but 
during diseases including atherosclerosis, SMCs undergo functional changes 
that contribute to pathology. Chronic inflammation in the vasculature exacerbates 
disease progression.  Acute phase serum amyloid A (SAA) is up-regulated during 
inflammation and expressed in atherosclerotic lesions.  Previous work in our 
laboratory demonstrated that SAA activates secretory phospholipase A2 group 
IIA (sPLA2), whose products impact cellular cholesterol homeostasis.  It was 
hypothesized that SAA promotes cholesterol trafficking from the plasma 
membrane to the endoplasmic reticulum (ER) in an sPLA2-dependent manner.  
SAA induced SMC cholesterol accumulation in the ER.  Levels of plasma 
membrane cholesterol decreased, confirming that cholesterol moved from the 
plasma membrane to the ER.  Another family member, (cytosolic phospholipase 
A2, group IV), was also required for SAA-induced sPLA2 activation and 
cholesterol mobilization.  SAA activated neutral sphingomyelinase and blocking 
this activity inhibited cholesterol trafficking.  These studies show that SAA 
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activated sPLA2 which activated neutral sphingomyelinase. As a result, 
sphingomyelin was cleaved, which liberated cholesterol for movement to the ER.  
Additional studies demonstrated that SAA repressed expression of SMC 
contractile markers including Acta2 and Myh11.  Toll-like receptor 2 (TLR2) is an 
SAA receptor implicated in atherogenesis and it was hypothesized that TLR2 
plays a role in SAA-mediated phenotype/gene changes.  The TLR2 ligands, FSL 
and Pam3CSK4, down-regulated SMC contractile marker expression.  
Knockdown of TLR2 demonstrated that SAA-mediated phenotype modulation 
was TLR2-dependent.  SAA, FSL, and Pam3CSK4 also induced mRNA 
expression of pro-inflammatory and adhesion genes, changes inhibited by TLR2 
knockdown.  SAA repressed activity of the αSMA promoter, demonstrating 
transcriptional regulation.  Myocardin, a transcription factor required to drive 
expression of SMC contractile genes, was down-regulated by SAA and FSL.  
Myocardin overexpression abrogated SAA- and FSL-mediated repression of the 
αSMA and SM22α promoters.  These studies demonstrate that SAA promoted a 
phenotypic switch through activation of TLR2 and down-regulation of myocardin 
expression. Taken together, novel SAA- and TLR2-mediated mechanisms of 
cholesterol trafficking and phenotypic modulation in SMCs are shown. 
Importantly, this work uncovers previously unknown effects of TLR2 signaling on 
vascular SMCs and provides a context by which TLR2 activation and lesion-
associated SAA may promote atherosclerosis. 
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INTRODUCTION 
The cardiovascular system 
Vascular structure and function 
The vascular system consists of a vast network of arteries, veins, and 
capillaries allowing for the movement of blood.  By transporting oxygen, nutrients, 
hormones, and cellular waste to and from cells of the body, this extensive 
network of vessels maintains cell homeostasis.  The vessels, in conjunction with 
the heart and blood, make up one component of the cardiovascular system, 
which together with the lymphatic system forms the overall circulatory system (1).   
While their physiological function can vary greatly depending on regional 
and organ context, blood vessels generally consist of three distinct layers.  Lining 
the lumen is the tunica intima (intima).  Generally the thinnest layer, the intima 
consists of a single layer of endothelial cells on a thin layer of basement 
membrane and, in larger vessels, a peripheral sheet of extracellular matrix 
(ECM) (1,2).  The endothelial layer is critically important for vascular function as it 
forms a barrier between the vessel and blood that can transduce and integrate 
both biochemical and mechanical signals to the vessel wall (3). In arteries, 
organized layers of internal elastic laminae provide flexibility and stability for the 
endothelial cell sheet. The size and development of these laminae vary 
proportionally to the size of the artery (1).   
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Underlying the intima is the tunica media (media), comprised mainly of 
smooth muscle cells (SMCs), elastin fibers, collagen, and proteoglycans.  
Thickness and organization of the media varies proportionally to the size of the 
vessel and, in general, is thicker in arteries compared to veins.  The largest 
arteries e.g. the aorta, contain multiple elastic sheets or laminae, interspersed 
between layers of SMCs thereby facilitating the increased structural demand of 
these vessels.  The majority of vascular SMCs within the media are 
concentrically arranged and their contraction regulates vascular tone by altering 
vessel diameter (1,2,4,5). 
The outermost layer is the tunica adventitia (adventitia), consisting mainly 
of collagen, secreted by adventitial fibroblasts.  In larger vessels, particularly 
arteries, elastin fibers are present and, in the largest vessels, these form the 
external elastic lamina which borders the boundary of the medial and the 
adventitial layers (1,2).  In addition to the rich collagen and elastin ECM, 
progenitor and immune cells, as well as lymphatic and nerve tissue pervade the 
adventitial stroma, forming a very complex and heterogeneous layer (6,7).  A 
network of micro-vessels called the vasa vasorum infiltrates the adventitia of 
large vessels, providing nutrients and oxygen where diffusion alone cannot 
sustain the tissue (1). 
Vascular SMCs 
Vascular SMCs are an essential component of the vascular system; 
during development and maturation of the vasculature SMCs perform 
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biosynthetic, proliferative, and contractile roles within the vessel wall (8).  During 
embryogenesis, as the vascular system is forming, SMCs are the major source of 
vessel wall ECM components (9).  These cells are characterized by their high 
rate of synthesis and deposition of elastin, collagen, and proteoglycans (10).  In 
addition, these cells undergo changes in proliferation enabling medial expansion 
to accommodate the size of the developing vessel (9).   
As the vasculature matures, medial SMCs become quiescent and undergo 
gene expression changes that down-regulate the synthetic capabilities of the 
cells (9).  Over time these maturing SMCs begin to express the components 
needed to form the contractile apparatus.  Considered the contractile phenotype, 
these cells regulate vascular tone, blood pressure, and blood flow by contracting 
and relaxing to alter vessel diameter (11).  The contractile genes expressed by 
mature, differentiated SMCs are generally considered as markers for their 
identification and include: smooth muscle α-actin (αSMA), smooth muscle myosin 
heavy chain (SM-MHC), h1-calponin, SM22α, and smoothelin (12–14).  Promoter 
mutation studies have shown that the expression of nearly every SMC marker 
gene is dependent upon one or more CArG [CC(AT)6GG] elements or boxes 
within their gene promoters and/or intronic sequences (15–18).  CArG elements 
are bound by the transcription factor, serum response factor (SRF).  A member 
of the MADS (Mcm1 and Arg80 in yeast, agamous and deficiens in plants, and 
SRF in animals) domain-containing family of transcription factors, SRF was 
originally named due to its ability to bind to a serum response element on the 
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promoter of the immediate early transcription factor c-fos (19).  SRF binds CArG 
elements as a dimer, with both dimerization and DNA binding occurring through 
its MADS box domain (12,20).   
Differential control of SRF target gene expression is largely via the 
interaction of SRF with signal-regulated or tissue-specific regulatory cofactors.  
Two families of signal-related SRF cofactors have been characterized. The 
ternary complex factor (TCF) family is made up of Ets domain containing 
proteins, Elk-1, SIN1-associated protein (SAP-1), and net.  Members of this 
family are activated by mitogen activated protein (MAP) kinase phosphorylation 
and bind DNA Ets motifs adjacent to CArG boxes within the promoters of 
immediate-early growth genes. The second family is made up of members of the 
myocardin-related transcription factor (MRTF) family and includes: myocardin, 
MRTF-A (also referred to as MAL, MKL1, or BSAC) and MRTF-B (also referred 
to as MKL2, or MAL16).  These family members contribute to SRF transcription 
of muscle-specific differentiation genes (21).  While the TCF family of cofactors 
recognizes Ets motifs adjacent to CArG boxes, no sequence-specific interaction 
sites near CArG elements have been identified for the MRTFs (22).  Four major 
myocardin isoforms are expresses in mouse, rat, and human tissues (23).  Two 
of these are alternatively spliced mRNAs resulting in a longer and a shorter 
isoform enriched in cardiac and smooth muscle tissue respectively (24,25).  
MRTF-A and MRTF-B activities are controlled by Rho-family GTPase signaling 
and levels of monomeric G-actin, such that the these co-activators are 
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sequestered in the cytoplasm through binding of their RPEL domains to G-actin 
(26).  In contrast, the myocardin RPEL domain does not bind monomeric actin, 
and therefore it is solely localized within the nucleus (27). 
Myocardin is of critical importance for controlling the expression of SMC 
differentiation genes.  Homozygous loss-of-function studies in mouse embryos 
resulted in lethality by embryonic day 10.5 and no signs of SMC-selective gene 
expression (28).  Multiple studies have demonstrated the ability of myocardin to 
selectively induce expression of all CArG-dependent SMC marker genes (12).  
Consistent with this, expression of dominant-negative myocardin or siRNA-
induced myocardin knockdown represses activity of the promoter for the Tagln 
gene that codes for SM22α (29).  Overall, myocardin is critical to SMC-specific 
marker gene transcription and its availability within the nucleus may represent a 
regulatory step for controlling SMC differentiation. 
The synthetic and contractile states discussed above represent the 
extremes of the SMC phenotype continuum (5).  SMCs, unlike other muscle 
types, remain remarkably plastic in their ability to undergo reversible changes in 
phenotype in response to environmental cues (30). While phenotype switching 
appears advantageous, such that the SMC can participate in vascular repair 
under normal physiological stresses, the highly plastic nature of the SMCs 
predisposes the cells to aberrant phenotype switching when exposed to 
pathological cues/signals that can contribute to vascular disease (31). Multiple 
lines of evidence implicate SMC phenotype switching as having a major role in 
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several diseases including: atherosclerosis, cancer, hypertension, and restenosis 
after angioplasty or bypass (8,31,32).  The role of SMC phenotypic switching in 
atherosclerosis will be discussed further below. 
Atherosclerosis 
Atherosclerosis: initiation and progression 
Atherosclerosis is the underlying cause of many cardiovascular disease 
complications including unstable angina, myocardial infarction, stroke, and 
sudden cardiac death (3).  Deaths from cardiovascular disease-related 
complications remain the number one killer in the United States and worldwide 
(33,34).  Atherosclerosis is a progressive disease characterized by chronic 
vascular inflammation mediated by innate and adaptive immune processes, 
marked by lesions that accumulate lipids as well as monocytes/macrophages, 
lymphocytes, and SMCs in the intima of medium to large sized arteries 
(2,3,35,36).  Important genetic and environmental risk factors associated with 
atherosclerosis have been elucidated and include elevated levels of low-density 
lipoproteins (LDL), low levels of high-density lipoproteins (HDL), elevated blood 
pressure, genetic history, diabetes and obesity, high-fat diet, smoking, gender 
(male), and systemic inflammation (2).   
Early lesions called “fatty streaks” mark an early stage of atherosclerotic 
disease (37) and these can begin to develop in large arteries, such as the aorta, 
as early as the first decade of life (2).  Endothelial dysfunction, marked by 
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nuclear factor κB (NF-κB) activation is evident, in particular at sites of disturbed 
laminar blood flow (i.e. bends and branches), and allows for retention and entry 
of LDL into the subendothelial space (35).  Modification of these particles, either 
by oxidation, enzymatic attack, and/or aggregation elicits an inflammatory 
response that promotes expression of various cell adhesion molecules by 
endothelial cells. Vascular cell adhesion molecule-1 (VCAM-1), up-regulated by 
endothelial cells under these conditions, is important for the recruitment and 
adherence of monocytes and lymphocytes to the site of lesion development (38).  
Similarly, intercellular adhesion molecule-1 (ICAM-1) was shown to contribute to 
monocyte recruitment as gene deletion significantly reduces the number of 
monocytes in lesions of apolipoprotein-E (apoE) deficient mice (39). Roles for E-
selectin and P-selectin have also been demonstrated such that their loss 
significantly reduces monocyte entry in an apoE deficient model (40).  Finally, 
monocyte chemoattractant protein-1 (MCP-1) is a critical regulator of monocyte 
migration into the subendothelial space (41).  Endothelial dysfunction is also 
characterized by the up-regulation of expression of various proinflammatory 
cytokines [interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, interferon 
(IFN)-γ], chemokines, ECM proteins, growth factors and micro-RNAs, all of which 
may contribute to lesion formation (3,42–46) 
The monocytes recruited into the subendothelium differentiate into 
macrophages, mediated by macrophage colony-stimulating factor (47).  
Expression of scavenger and Toll-like receptors (TLRs) is up-regulated and the 
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cells accumulate cholesterol (discussed below) (48).  Macrophages promote the 
proinflammatory environment with additional growth factors, cytokines and 
secretion of matrix metalloproteases (MMPs), the latter of which likely contributes 
to plaque rupture (3). 
Complex lesion progression proceeds with phenotype switching of SMCs 
and proliferation and migration from the medial layer into the expanding 
subendothelium or neointima (49).  Initially, SMCs confer atheroprotective effects 
to the developing lesion where they continue to proliferate and migrate, 
contributing to outward remodeling of the vessel.  In addition, they synthesize 
and deposit a collagen-rich matrix that forms a fibrous cap over the lesion that is 
capable of protecting against plaque rupture and thrombosis (2,3,50).   Over time 
however, continued inflammatory insults within the plaque promote lesion 
progression.  Expression of receptors that ingest cholesterol lead to SMC-derived 
foam cell formation in the lesion (51).  Inflammatory cytokines, as well as 
oxidized LDL (oxLDL) promote apoptosis of both SMC and macrophage foam 
cells, resulting in the release of oxidized and insoluble lipids that accumulate and 
contribute to the formation of the lipid-rich “necrotic core” (49).  In addition, IFN-γ 
inhibits SMC collagen synthesis, weakening the forming fibrous cap and 
contributing to a less stable plaque (52).  Finally, aberrant SMC MMP expression 
can thin the fibrous cap thus leading to a destabilized or “vulnerable” plaque (46). 
While intimal thickening in extremely advanced lesions does have the 
capacity to lead to acute coronary events resulting from artery stenosis, plaque 
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rupture and thrombosis contribute more frequently to clinical manifestations of 
atherosclerosis (2,49,53).  Rupture releases plaque lipid and tissue factor to 
blood which initiates the coagulation cascade, resulting in platelet adherence and 
thrombosis (49).  Plaque rupture occurs more frequently at sites of thinned 
fibrous cap (2) and as discussed above, SMCs, in conjunction with other cell 
types contribute to this process. 
Cholesterol metabolism in atherosclerosis 
Cellular cholesterol homeostasis is critical to normal cellular functions 
(54).  Cellular compartmentalization of cholesterol is tightly regulated and varies 
according to cell type.  Most cellular free cholesterol resides in the plasma 
membrane while other major compartments containing free cholesterol include 
the endoplasmic reticulum (ER) and the trans-Golgi network (55).  Cellular 
cholesterol is derived from two major sources.  The first and major mode of 
acquisition for cellular cholesterol is through the endocytosis of LDL first 
described by Brown and Goldstein (56) where LDL is taken up through the LDL 
receptor (LDLr).  Cholesterol within the LDL particle is released by hydrolysis 
inside lysosomes. This cholesterol can then be esterified in the ER by the 
enzyme acetyl-coenzyme A acetyltransferase (ACAT), forming cholesteryl esters 
which can be stored intracellularly.  The second source of cellular cholesterol is 
through synthesis that occurs within the ER (57).  ER cholesterol levels regulate 
cholesterol synthesis, as well as the expression of the LDLr, the latter regulating 
uptake of extracellular cholesterol (54,58).  Cholesterol movement to and from 
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and regulation within the ER is are critical to overall cell homeostasis and 
perturbations to this process during disease can have deleterious effects to the 
cell.  Cholesterol is essential for cell membranes, where it can modulate 
membrane rigidity, fluidity, and permeability (59).  Cholesterol membrane 
distribution can also impact signaling pathways.  For instance, cholesterol was 
recently shown as a regulator of the scaffold protein NHERF1 (60) that mediates 
activation of cystic fibrosis transmembrane conductance regulator (60).   
Lipoprotein retention within the intima precedes monocyte infiltration and 
is an important initiating factor in atherosclerosis (2,46,49).  LDL retention in the 
vessel wall mainly involves the interaction of apoB-100 and matrix proteoglycans 
(61), however proteoglycan binding to apoB-48 has also been demonstrated 
(62).  Macrophage foam cell formation is not facilitated by uptake of native LDL; it 
was proposed by Brown and Goldstein that LDL was somehow modified in the 
vessel wall and that these modifications enable rapid uptake and intracellular 
cholesterol accumulation (63).  Indeed, lipid oxidation of LDL results in modified 
oxLDL (64) and LDL protein modification leads to loss of recognition by the LDLr 
with a shift to recognition by scavenger receptors on macrophages (65).  Cellular 
uptake of LDL under these conditions is not regulated by intracellular cholesterol 
content leading to the massive accumulation of cholesterol contributing to the 
foamy cytoplasmic characteristic of a foam cell (66).  Vascular SMCs are also 
capable of undergoing foam cell transition in response to modified lipoproteins 
(46,67).   
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LDL modification involves reactive oxygen species, probably produced by 
activated endothelial cells.  However, several other enzymes present within the 
human atherosclerotic lesion also contribute to LDL modification (2).  Secreted 
phospholipase A2 (sPLA2) promotes atherosclerosis, in particular groups III and V 
sPLA2 (68).  These acute phase proteins cleave fatty acids at the sn-2 position, 
resulting in the release of arachidonic acid and lysophospholipids (69).  In 
addition, group IIa sPLA2 has also been demonstrated to be involved in 
atherogenesis (70).  LDL modified by these enzymes binds more rapidly to 
proteoglycans, leading to aggregation.  These LDL aggregates are then more 
rapidly taken up by macrophages and SMCs which contributes to foam cell 
formation (46,66).  Sphingomyelinases also promote enhanced lipoprotein 
aggregation, retention, and uptake within the developing lesion (2,46).  
Sphingomyelin, degraded by sphingomyelinase enzymes, is known to inhibit 
group V sPLA2 (71).  Increased sphingomyelinase in the lesion would 
presumably increase sPLA2 activity resulting in LDL aggregation and 
modification. 
Foam cell formation in macrophages and SMCs is largely driven by 
increased expression of scavenger receptors.  Oxidized LDL is taken up by a 
variety of scavenger receptors including; class A receptors (SR-A), class B (SR-
BI, CD36), and class E (LOX-1) (72).  Of these receptors, SR-A and CD 36 have 
been studied extensively and appear to be critically important during 
atherosclerosis.  Mice deficient in either of these receptors have significant 
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reduction in atherosclerotic lesions (73,74). In addition to the receptors that up-
regulate cholesterol intake, pro-inflammatory cytokines (IL-1β, IFN-γ, TNF-α), 
contribute to foam cell formation by down-regulating cholesterol efflux pathways 
that are normally responsible for off-loading excess cellular cholesterol (75).     
As macrophages ingest modified LDL, cholesteryl ester is hydrolyzed by 
lysosomal acid lipase A.  Loss of this enzyme promotes atherogenesis, 
presumably due to excess lipid accumulation in the cell (76).  Loss of ACAT1 in 
hyperlipidemic mice causes increased atherosclerosis presumably due to 
progressive cell death from free cholesterol accumulation which leads to 
cholesterol crystallization in foam cells (77,78).  In addition, cholesterol crystals 
facilitate secretion of proinflammatory cytokines such as Il-1β and IL-18 (79), 
contributing to the growing inflammatory cycle within the lesion. 
Foam cells are vital contributors to the progression of atherosclerosis.  
Lipid metabolism, in particular cholesterol esterification, plays an important role in 
foam cell development and aberrant cholesterol movement and metabolism can 
affect cellular signaling.  
SMCs in atherosclerosis 
As discussed, SMCs are a vital component of the vascular wall.   In the 
developed vasculature, medial SMCs regulate blood pressure and blood flow 
distribution.  Following initial endothelial cell activation and fatty streak lesion 
formation, progression to a complex plaque is marked by the arrival of SMCs (or 
SMC-like cells) within the intima where they deviate from their normal contractile 
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phenotype thereby promoting atherogenesis (2,46,49,53,80).  The origin of these 
SMCs within the intima has been debated within the field.  Historically, it was 
thought that differentiated, contractile SMCs migrate from the media to the intima 
where they undergo a phenotype modification classically marked by the loss of 
expression of contractile proteins (2).  This has recently come into question due 
to lack of definitive lineage tracing studies (3).  Moreover, it was shown that 
macrophages express classical SMC markers in response to thrombin (81), 
suggesting that cells expressing SMC markers found in the lesion could be 
derived from macrophage-like cells.  Likewise, a fraction of cells positive for SMC 
markers are of the myeloid lineage (82).  On the other hand, numerous studies 
do still support that SMCs within the atherosclerotic lesion originate from the local 
vessel wall and not circulating progenitors (83).  Most likely, SMCs within the 
atherosclerotic plaque originate from many sources depending on the specific 
signaling events occurring in the developing plaque. 
Studies show that release of growth factors and cytokines by endothelial 
cells following initial intimal injury promotes migration and proliferation of SMCs 
from the media towards the intima (80).  Inflammatory IL-1 and IL-4 induce 
synthesis of a range of MMPs by SMCs (84,85).  Induction of MMPs results in 
degradation of the normal ECM surrounding SMCs in the medial layer facilitating 
cell migration to the intima (86). Increased IL-6 production in response to TLR2 
activation promotes SMC migration in vitro via both the p38 mitogen-associated 
protein kinase (MAPK) and extracellular signal-regulated kinase 1/2 signaling 
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pathways (87).  Platelet-derived growth factor (PDGF) is a potent promigratory 
stimulus for SMCs (88).  Additionally, osteopontin, a matrix glycoprotein whose 
expression increases during atherogenesis, enhances SMC migration via αVβ3 
signaling (89).  Promigratory roles for the matrix proteins, collagens I and IV and 
laminin have also been shown (90).  Some mediators of SMC proliferation 
include: PDGF-BB (11), thrombin (91), and oxidized phospholipid (92).  
Many roles for SMCs during plaque progression have been shown and 
reviewed extensively, some of which were described above (51).  ECM 
production by SMCs within the intima contributes to the formation of a fibrous 
cap, which is known to stabilize the plaque.  SMCs also express scavenger 
receptors, giving rise to a significant fraction of lipid-laden cells within the lesion 
(93).  Induction of VCAM-1 and ICAM-1 expression by SMCs within the intima 
contributes further to monocyte and macrophage recruitment and retention within 
the growing plaque (94,95).   
Common to all of these functions is the ability of the SMC to undergo 
phenotypic modulation, demonstrating the critical importance of this defining 
feature of these cells.  As discussed, SMCs differentiate from a synthetic 
phenotype during embryogenesis to the contractile phenotype during vascular 
maturation (10).  Recent findings suggest the existence of non-migratory, non-
proliferating SMCs that express various inflammatory markers including VCAM-1; 
indicating additional complexity of the SMC phenotypic continuum (32).   
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Many signaling pathways promote the SMC inflammatory phenotype.  The 
c-jun N-terminal kinase (JNK) pathway induces expression of the 
proinflammatory genes, VCAM-1 (96) and MCP-1 (97), in SMCs.  Activation of 
NF-κB, drives expression of many inflammatory molecules, in SMCs in both 
atherosclerosis (98) and after vessel injury (99).  Nuclear factor of activated T-
cells (NFAT) plays an important role in SMC migration and proliferation during 
disease (100); however, its role in SMC inflammatory gene expression has not 
been explored.  Janus kinase-signal transducer and activator of transcription 
(JAK-STAT), another pathway classically associated with inflammatory cytokine 
expression, is required for angiotensin II-mediated SMC proliferation and 
migration (101).  Additionally, STAT3 is required for angiotensin II-induced 
expression of the IL-18 receptor (102) as well as IL-6-dependent expression of 
MCP-1 (103) in SMCs.  
Soluble, extracellular mediators associated with atherosclerosis also 
contribute to the acquisition of the SMC inflammatory phenotype (32).  Oxidized 
LDL treatment of SMCs in culture stimulates expression of MCP-1, TNFα, and 
VCAM-1 (104,105).  Oxidized phospholipid also represses SMC differentiation 
while activating expression of MCP-1 and MCP-3 (92,106).  In addition to soluble 
mediators, changes to the matrix composition in the atherosclerotic lesion may 
promote inflammatory gene expression in SMCs.  Binding to fibronectin, up-
regulated and secreted by SMCs during disease (107), activates NF-κB (108) 
possibly leading to induction of proinflammatory gene expression.  Osteopontin 
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deposition is enhanced in atherosclerotic lesions and its knockdown by siRNA 
reduces angiotensin II-mediated secretion of IL-6 in SMCs (109).  Finally, 
hyaluronic acid stimulates SMC VCAM-1 expression through CD44 which 
promotes atherogenesis (110). 
SMCs gain characteristics of an inflammatory phenotype through various 
signaling pathways mediated by soluble plaque components and/or ECM 
changes within the developing lesion.  Expression of proinflammatory molecules 
by SMCs exacerbates the already existing inflammatory cycle present from 
macrophages and other immune cells leading to the further progression of 
atherosclerosis. 
The acute phase response 
To fight infection, tissue damage, trauma, or inflammation, the body 
undergoes a series of biochemical and physiological changes called the acute-
phase response (111).  Innate immune cells are activated as a “first-line of 
defense” to provide a rapid response to injury compared to the slower more 
specific responses by B- and T-cells of the adaptive immune system (111,112).  
To recognize harmful agents, the innate immune system uses a number of 
pattern recognition receptors (PRR), including various scavenger receptors and 
TLRs (113,114).   
A key component of the acute phase response is the elevated hepatic 
synthesis of proteins involved in coagulation, lipid metabolism and the 
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complement system (111). Key acute phase proteins include C-reactive protein 
(CRP), serum amyloid A (SAA), platelet-activating factor acetylhydrolase, and 
paraxonase-1 (111,112).  Some of the acute-phase reactants, including CRP and 
SAA, can also be chronically expressed, resulting in a low-grade inflammatory 
state that has been associated with increased risk of vascular disease including 
atherosclerosis (115).  CRP, and to a lesser extent SAA, were found to be 
predictive for risk of cardiovascular events in women (116).  Additional studies 
further support an association for SAA and coronary artery disease (117,118).       
Serum amyloid A 
SAA is a family of highly conserved acute phase proteins synthesized 
primarily by the liver in response to inflammatory stimuli (119).  Circulating serum 
levels of SAA can rise as high as > 1 mg/mL in response to endotoxin challenge 
(120).  The SAA family is comprised of acute-phase isoforms (SAA-1, SAA-2, 
and SAA-3) and a constitutive member (SAA-4) (119).  It has been suggested 
that SAA-3 is a pseudogene in humans, but in mice, it appears to be an acute-
phase reactant secreted by adipocytes (121).  A recent study identified human 
SAA-3 protein translated from SAA-2-SAA-3 fusion transcripts in many human 
cell lines (122).  Analysis of SAA-1 revealed a section of the protein capable of 
forming amphipathic α-helices consistent with apolipoproteins (123).  During the 
acute phase response, SAA becomes an apolipoprotein on HDL, resulting in 
larger particle size (124).   
18 
While serum SAA is up-regulated during the acute phase response, the 
impact of chronic elevation of SAA during metabolic and disease states is 
uncertain.  Modest, chronic elevation of SAA was found in patients with chronic 
inflammatory diseases such as systemic lupus erythematosus or rheumatoid 
arthritis (125,126).  In addition, SAA localizes to murine atherosclerotic lesions 
(127).  SAA deficiency in Apoe-/- mice had no effect on lipid deposition or lesion 
area in atherosclerosis (128).  However, in the Ldlr-/- model, loss of SAA resulted 
in reduced lesional area in the ascending aorta suggesting a pro-atherogenic role 
for SAA (129).  The contrast between these two reports exemplifies that fact that 
the impact of SAA on the development of atherosclerosis is unknown, and both 
pro- and anti-atherogenic functions have been proposed (119,130).  Future 
research addressing the importance of SAA for atherogenesis, as well as, as 
studies that identify potential atherosclerotic process mediated by SAA will 
contribute to our knowledge of atherosclerotic disease.   
HDL-associated SAA inhibits reverse cholesterol transport (131,132), 
resulting in increased cholesterol availability for peripheral tissues as needed 
during an acute phase response but is potentially pro-atherogenic at sites of 
lesion development.  Additionally, SAA-associated HDL binds proteoglycans with 
high affinity where their retention in lesions leaves them susceptible to oxidative 
and enzymatic modification that renders them more atherogenic (133).  SAA also 
increases vascular SMC proteoglycan synthesis resulting in increased LDL 
binding affinity (134).  In addition, SAA increases sPLA2 expression and 
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activation in SMCs, which may have additional effects on LDL modification (135).  
Further effects on vascular SMCs by SAA suggest a role for acute-phase SAA to 
promote migration of SMCs in sites of inflammation such as a developing 
atherosclerotic lesion (136).  In addition, our laboratory has demonstrated that 
SAA activates MMP9 expression and down-regulates elastin expression in SMCs 
(137).  Atherogenic effects for SAA on vascular endothelium have also been 
described.  SAA promotes both monocyte chemotaxis and adhesion to the 
vascular endothelium (138).  Moreover, SAA promotes the expression of many 
inflammatory cytokines such as IL-6, IL-8 and MCP-1 that impair nitric oxide 
bioactivity and endothelial function (139). 
Lipid-free SAA decreases endogenous SMC lipid biosynthesis (140), a 
potentially anti-atherogenic effect.  Additionally, reports suggest a positive role for 
SAA in promoting endothelial functions including increasing endothelial 
proliferation and production of nitric oxide and prostaglandin I2 (141,142).  
To date, at least 6 receptors for SAA have been demonstrated.  Formyl 
peptide receptor 2 facilitates chemoattractant ability towards SAA (143) as well 
as the ability of cells to up-regulate expression of IL-8 (144) and MMP9 (145).  In 
addition, efflux of cholesterol in cells by SAA was demonstrated to occur through 
SR-BI and CLA-1 (146,147).  TLRs, important during innate immune responses, 
have also been demonstrated as SAA receptors.  TLR4 mediates TNFα 
production in feline peripheral blood monocytes (148) as well as endothelial cell 
nitric oxide production (142).  TLR2/1 heterodimer was demonstrated as the 
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preferred receptor for SAA, stimulating the expression of IL-1β, TNFα, and IL-10 
in HeLa cells (149).  Roles for TLR2 in mediating SAA-induced expression of IL-
23p19 (150) and G-CSF have also been shown (151).  Most recently, TLR2 
activation was shown to be important for SAA-induced expression of IL-33 and 
M2 macrophage markers in monocytes and macrophages (152,153).  TLRs 
appear to be important for the development of atherosclerosis, discussed in more 
detail below (154).  The endogenous and/or exogenous ligands that activate 
TLR2 in the context of atherogenesis are unknown.  Studies examining 
atherogenic SAA-mediated processes that occur through TLR2 activation are 
potentially important and may provide further mechanistic links between TLR 
signaling and atherosclerosis.     
Toll-like receptors 
TLRs are critical receptors of the innate immune response and are vital for 
host defense against bacterial and viral pathogens.  Loss of regulation of TLR 
signaling, as well as recognition of self-molecules by TLRs, is strongly associated 
with pathogenesis of inflammatory and autoimmune diseases (155).  As such, 
certain TLRs are increasingly considered as key modulators of atherosclerotic 
disease (154,156). 
TLRs are type 1 transmembrane proteins with ectodomains containing 
leucine-rich repeats that mediate the recognition of pathogen-associated 
molecular patterns (PAMPs), transmembrane domains, and Toll-IL-1 receptor 
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(TIR) domains required for downstream signal transduction (155).  In human, 10 
TLRs have been discovered while mice have 12 functional TLRs.  Studies in 
mice have demonstrated that each TLR has a distinct function in terms of PAMP 
recognition and immune responses (157).  Signal transduction begins upon 
ligand binding by TLRs.  Mainly, TLRs form homodimers; however 
heterodimerization of TLR1/2, TLR2/6 and TLR4/6/CD36 also occurs readily 
(158,159).  Upon ligand stimulation, the TIR-domain binds to adapter proteins 
including myeloid differentiation primary-response protein 88 (MyD88), TIR-
domain containing adaptor protein (TIRAP), TIR-domain containing adaptor 
protein inducing IFN-β (TRIF), and the TRIF-related adaptor molecule (TRAM).  
Two distinct signaling pathways exist: the MyD88-dependent and the MyD88-
independent/TRIF-dependent pathways (156).   MyD88 appears to play a key 
role in the processes of atherosclerosis.  MyD88 deficiency reduces 
atherosclerosis mediated in part, by reduced macrophage recruitment to the 
artery wall (160).  Similarly, another study showed that loss of MyD88 diminishes 
aortic atherosclerosis (161). 
TLR2 and TLR4 are highly studied with regard to atherosclerotic disease.  
Knockout of TLR2 in the Ldlr-/- mouse model reduces the development of 
atherosclerosis after 10 and 14 weeks of high fat diet (162).  Furthermore, TLR2 
expression is increased at sites prone to the development of atherosclerosis 
(163), suggesting a role for this receptor in mediating disease.  Interruption of 
TLR2 and Myd88 signaling inhibits NF-κB activation and MMP production in cells 
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isolated from human atherosclerotic lesions (164).  Finally, multiple studies have 
demonstrated a role for TLR2 in pathogen-mediated inflammatory 
atherosclerosis e.g. in response to oral infection with the pathogen P. gingivalis 
(165–167).  Apoe-/- mice in which TLR4 is knocked out, exhibit decreased 
atherosclerotic lesion development and monocyte infiltration into lesions (161).  
However, a different report demonstrated a protective role for TLR4 in the Apoe-/- 
model (168).  Additionally, TLR4 detects oxLDL and plays a role in the formation 
of foam cells during atherogenesis (169), contributing to this process to a greater 
extent than that of TLR2  (170).  While TLR2 and TLR4 have been implicated in 
atherosclerosis most frequently, TLR3, TLR7, and TLR9 may also play a role in 
disease.  Murine cytomegalovirus, a ligand of TLR3 and TLR9, exacerbates 
atherosclerosis (171,172).  Coxsackie B virus is an agonist for TLR7 and 
promotes cardiac lipid accumulation in mice (173). 
In addition to the classic exogenous TLR agonists such as various 
pathogens and their cell-wall components, endogenous agonists have been 
demonstrated for TLRs.  These ligands occur in mice that are not exposed by 
direct manipulation to known additional exogenous ligands (154).  In the absence 
of an administered exogenous agonist, TLR2 deficiency in Ldlr-/- mice decreases 
atherosclerotic plaque formation (154,162), however the endogenous ligand(s) 
responsible for TLR2 induction of atherosclerosis remains unknown.  The role of 
oxLDL phospholipids as TLR2 agonists has been studied (174,175) however the 
results are largely negative and other components of oxLDL have not been 
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studied.  Non-lipid candidate endogenous TLR2 ligands include: high-mobility 
group box 1 protein, hyaluronic acid fragments, and biglycan (154).  Finally, SAA 
was demonstrated to be functional ligand for TLR2 (149).  Identification of the 
factors responsible for activating TLR2 in the context of atherogenesis may 
provide novel targets for therapeutic treatment against the disease.   
Goals of research 
As introduced above, atherosclerosis involves chronic inflammation of the 
vascular wall resulting in the development of plaques marked by the 
accumulation of lipids, macrophages, and SMCs.  Aberrant SMC lipid 
metabolism and phenotypic modulation contribute to atherogenesis.  The role of 
SAA in atherosclerosis is not well defined.  In addition to circulating SAA, locally 
expressed SAA within the vessel wall and/or lesion may impact vascular cells 
during atherogenesis.  Identification of SAA-mediated processes in vascular 
SMCs will increase our understanding of atherosclerosis.  It will also be valuable 
to identify the molecules through which SAA acts to promote these changes.     
Our laboratory showed that SAA up-regulates SMC sPLA2 gene 
expression (135), It was hypothesized that SAA promotes trafficking of 
cholesterol from the plasma membrane to the ER in an sPLA2-dependent 
manner.  The mechanism whereby sPLA2 impacted cholesterol movement was 
explored.  Moreover, a hypothesis was formulated that SAA induces SMC 
phenotype modulation, and that this process is dependent upon the activation of 
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TLR2.  In particular, experiments were performed to determine if SAA and TLR2 
activation decrease expression of markers of the SMC contractile state.  In 
addition, studies examined changes in inflammatory markers to determine the 
status of the SAA-treated SMCs.  Intracellular mechanisms regulating changes in 
the SMC phenotype were also explored.   Lastly, the roles of SAA on cholesterol 
trafficking and SMC gene expression were studied to determine if these are 
dependent or independent pathways. 
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MATERIALS AND METHODS 
Isolation and culture of neonatal rat and mouse SMCs 
In accordance with the protocols approved by Boston University’s 
Institutional Animal Care and Use Committee, medial aortic SMCs were isolated 
from 3-day old Sprague-Dawley rats (Charles River Laboratories, Wilmington, 
MA) as previously described (176).  Thoracic and abdominal aortae were 
removed, placed in a Petri dish containing Dulbecco’s modified Eagle’s Medium 
supplemented with 100 units/mL penicillin, 100 µg/mL streptomycin, 0.1 mM 
minimum essential medium (MEM) non-essential amino acids, and 0.1 mM MEM 
sodium pyruvate (Cellgro by Corning, Tewksbury, MA) (DMEM) and stripped of 
adventitia.  The cleaned aortae were then rinsed in fresh DMEM briefly, minced 
using fine surgical scissors, and digested enzymatically in DMEM containing 0.5 
mg/mL collagenase (Type IA; Sigma, St. Louis, MO) and 0.125 mg/mL porcine 
pancreatic elastase (Sigma) with gentle stirring at 37°C for 30-45 minutes.  An 
equal volume of DMEM containing 20% fetal bovine serum (FBS; Atlanta 
Biologicals, Norcross, GA) was added to the resulting cell suspension to inhibit 
enzymatic activity.  The cell suspension combined with 2 DMEM washes was 
centrifuged at 400 x g for 10 minutes.  The supernatant was aspirated and the 
cell pellet resuspended in DMEM containing 20% FBS.  Cells were seeded at 5 x 
105 per cm2 cell culture flask in DMEM containing 20% FBS and maintained in a 
humidified incubator at 37°C with 5% CO2/95% air.  Media were changed the 
next day and twice per week thereafter.  Primary cultures were maintained for at 
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least 7 days, and then subcultivated by removing the media, washing the cells 
twice with warm (37°C) Hank’s Balanced Salt Solution (HBSS; Cellgro) and 
incubating with trypsin [0.05% trypsin/0.02% ethylenediaminetetraacetic acid 
(EDTA); Cellgro] for 5 minutes at 37°C, at which time DMEM containing 10% 
FBS was added to inhibit enzymatic activity.  The resulting cell suspension was 
centrifuged at 400 x g for 10 minutes.  The supernatant was aspirated and the 
cell pellet was resuspended in DMEM containing 10% FBS.  Cells were seeded 
at 2 x 104 cells per cm2.  Media were changed the next day and twice per week 
thereafter. 
Lipoprotein deficient serum preparation 
Lipoprotein deficient serum (LDS) was prepared from FBS as previously 
described (140).  All steps were performed on ice or at 4°C.  Potassium bromide 
was dissolved in FBS to achieve a density of 1.25 g/mL.  The serum was 
aliquoted into OptiSeal centrifuge tubes (Beckman Coulter, Palo Alto, CA) and 
subjected to ultracentrifugation using a 50.2Ti rotor (Beckman Coulter) at 48,000 
x g for 48 hours at 4°C.  The lipid-containing top fraction was removed using 
either a tube slicer or a syringe with a 16-gauge needle.  The lipoprotein-deficient 
bottom fraction was collected and dialyzed (Spectra/Por 6000-8000 molecular 
weight cut-off; Spectrum Medical Instruments, Houston, TX) against water for 3 
days, 0.01% EDTA for 1 day and phosphate buffered saline (PBS; Fisher 
Scientific, Waltham, MA) for 1.5 days.  All dialysates were changed twice daily.  
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Following dialysis, the serum was filter sterilized (0.2 µm), aliquoted and stored at 
-20°C. 
Cell culture and treatment 
Experiments were performed on cells in first or second passage. Cells 
were subcultivated as described above, seeded into 6-well plates for protein 
expression assays; 12-well plates for mRNA expression, lipid analysis, or 
sphingomyelinase assays; and 24-well or 96-well plates for luciferase assays.  
Media were replaced as described above and always one day prior to beginning 
an experiment.  Experiments were performed on cultures after they reached 
confluence (at least 7 days after plating) unless otherwise indicated (i.e. 
transfection experiments).  On the day of the experiment, media were removed, 
cells were washed twice with warm HBSS and DMEM containing 10% LDS was 
added.  If an inhibitor was used, it was added 1 hour prior to the start of the time 
at which agonists were added.  All time points in an experiment were started 
concurrently such that each time point was harvested at separate times. 
Recombinant human SAA and human SAA-1 (Peprotech, Rocky Hill, NJ) 
were dissolved in nuclease-free, sterile water (Ambion, Grand Island, NY) at a 
concentration of 2 mg/mL.  Synthetic TLR2 agonists, FSL-1 (FSL) and Pam3CSK 
(Pam) (Invivogen, San Diego, CA) were dissolved in the supplied endotoxin-free 
water at a concentration of 0.1 mg/mL.  Rat IL-1β and IFN-γ (eBioscience, San 
Diego, CA) were supplied in PBS containing 1% bovine serum albumin (BSA) at 
a concentration of 100 µg/mL.  Murine TNF-α (Peprotech) was dissolved in water 
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at a concentration 20 µg/mL.  The Akt inhibitor MK-2206 (Selleckchem, Houston, 
TX) was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 10 mM.  
Lysosomal inhibitors used include chloroquine (MP Biomedicals, Solon, OH; 
dissolved in HBSS at a concentration of 5 mM), bafilomycin A1 (Sigma; dissolved 
in ethanol (EtOH) at a concentration of 1 µg/mL), and U18666A (Sigma; 
dissolved in EtOH at a concentration of 0.1 mg/mL).  The cytoplasmic PLA2 
(cPLA2) inhibitor arachidonyl trifluoromethylketone (AACOCF3; Ascent Scientific, 
Cambridge, MA) was supplied in EtOH at a concentration of 5 mg/mL.  Chicken 
egg yolk sphingomyelin (Sigma) was dissolved in EtOH at a concentrations of 2.5 
mg/mL. 
For experiments studying lipid-associated SAA, HDL (Calbiochem, La 
Jolla, CA)-associated SAA was prepared in DMEM containing 10% LDS adding 
HDL (150 μg protein/mL) and the SAA (2 µM) before incubating this mixture at 
room temperature for 15 minutes while shaking, followed by 15 minutes at 37°C.  
Samples were then added to the cells and comparisons were made to similarly-
treated samples containing SAA or HDL alone.  Media and reagents were 
replaced twice weekly (i.e. every 3-4 days) for long-term studies and always the 
day before the cells were harvested.   
For knockdown experiments, cells were transfected with small interfering 
RNA (siRNA) targeting rat TLR2 (siTLR2) (siGenome SmartPool; Dharmacon, 
Lafayette, CO) or non-targeting control siRNA (siCtl) (Dharmacon).  
Transfections were performed with cells at 70% confluence using Lipofectamine 
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RNAiMax (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.  
On the day of transfection, media were removed, cells were washed twice with 
warm HBSS and DMEM without antibiotics containing 10% FBS (800 µl) were 
added. RNAiMax reagent and siRNA were added to Opti-MEM (Invitrogen) at 
room temperature and incubated for 10 minutes at room temperature to form 
reagent/siRNA complexes.  Two hundred µL of siTLR2 or siCtl complex was 
added to the cells such that the final concentrations were 3 µL/well RNAiMax and 
25 nM siRNA.  After 24 hours, transfection media were removed, cells were 
washed twice with warm HBSS and DMEM containing 10% FBS was added.  
After 24 hours, media were removed and the experiment was started under 
experimental conditions listed above.  
[14C]Oleic acid incorporation into cholesteryl ester 
Cells were cultured according to the conditions outlined above in 12-well 
tissue culture dishes and 24 hours (25 hour if an inhibitor was used) prior to the 
time of harvest, media were removed, cells were washed twice with warm HBSS 
and DMEM containing 10% LDS was added.  Prior to treatment, [14C]oleic acid 
complexed to BSA (0.1 mM; 0.43 µCi/mL) was added.  To form the [14C]oleic acid 
complex, oleic acid (Sigma) was first complexed to albumin by dissolving BSA 
(Sigma, fatty acid free) in 0.15 M NaCl at 37°C and dissolving sodium oleate 
(Sigma) in 0.15 M NaCl at 60°C.  The oleate solution was slowly added to the 
BSA solution with mixing and the final pH was adjusted to 7.4 using NaOH.  The 
final molar ratio of oleic acid to BSA was 5:1; the complex was stored at -20°C.  
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To prepare radioactive oleic acid, [14C]oleic acid in EtOH (NEC-317; Perkin 
Elmer, Waltham, MA) was evaporated to dryness under N2 gas and the non-
radioactive oleic acid/albumin was added.  The mixture was vortexed for 1 
minute and incubated for 1 hour at 4°C before it was added to cell cultures.   
To harvest cells, media were removed on ice and cells were washed with 
PBS containing 1% fatty acid free BSA (1 mL/well; 4°C), followed by 3 washes 
with 1 mL cold PBS.  Lipids were extracted with 1 mL hexane/isopropanol 
solution (3:2 vol/vol) for 1 hour at room temperature.  An additional wash (0.5 mL 
of this solution) was combined with the original extract.  Following lipid extraction, 
cell protein was extracted in 0.2 N NaOH for 1 hour at room temperature. Lipid 
and protein extracts were stored at -20°C. 
Lipid extracts were dried under N2 gas and redissolved in 35 µL toluene 
with 1 minute of vortexing.  [14C]cholesteryl oleate was measured by thin layer 
chromatography (TLC).  The redissolved lipids (30 µL) and lipid standards were 
spotted onto polyester backed silica gel TLC plates (Whatman, Pittsburgh, PA).  
The spotted samples were dried completely under N2 and the TLC plates were 
developed in a chamber of hexane/diethyl ether/glacial acetic acid (70:30:1 
vol/vol/vol).  Lipid spots were visualized on the TLC plates using iodine vapor and 
the cholesteryl oleate band was cut from the plate and [14C] measured by liquid 
scintillation spectrometry or [14C] was measured using an autoradiograph imager 
(Perkin Elmer). To normalize lipid measurements, protein was quantified as 
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described above.  Data are expressed as [14C]cholesteryl oleate (cpm)/mg 
protein ± SD (n=3). 
Plasma membrane cholesterol assay 
Cells were cultured under conditions outlined above.  One day prior to 
treatment, media were removed, cells washed twice with warm HBSS and 
DMEM containing 10% FBS was added.  Cells were incubated with 
[3H]cholesterol (2-3 µCi/ml) (NET-139; Perkin Elmer) overnight to equilibrate into 
the cellular cholesterol pool.  Cells were washed 5 times with warm HBSS to 
remove excess [3H]cholesterol and the cells were treated with SAA for 7 days 
according to the experimental conditions described above, at which time the 
cholesterol oxidase-sensitive pool of cholesterol was determined essentially as 
previously described (177).  Media were removed on ice, cells were washed with 
1 mL of Tris buffered saline (TBS) containing 1% fatty acid free BSA at 4°C, 
followed by 2 washes with PBS at room temperature.  Cells were fixed in 1% 
glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) in PBS for 10 
minutes at room temperature and then washed 3 times for 2 minutes each with 
PBS at room temperature.  Cells were then treated for 30 minutes at 37°C with 1 
mL DMEM (no antibiotics, serum, or supplements) containing sphingomyelinase 
(EMD Millipore 567707, Billerica, MA; 0.1 U/mL) with or without cholesterol 
oxidase (Sigma C8649; 2 U/mL).  After washing with PBS twice for 2 minutes 
each, cell lipids were extracted, dried down with N2, and redissolved as 
described previously.  The samples and standards of were spotted onto TLC 
32 
plates, dried under N2, and developed in a chamber of hexane:diethyl 
ether:glacial acetic acid (130:30:2 vol/vol/vol).  Lipid spots were visualized on the 
TLC plates using iodine vapor and bands corresponding to cholesterol and 
cholestenone were determined based on the standards.  These bands were cut 
removed from the plate and [3H] was measured by liquid scintillation 
spectrometry.  [3H]Cholestenone as a percentage of the total [3H] cholesterol was 
calculated as follows: {[3H]cholestenone (cpm)/{[3H]free cholesterol (cpm) + 
[3H]cholestenone (cpm)} × 100.  Data are expressed as percentage 
[3H]cholestenone  ± SD (n=3). 
Quantitative polymerase chain reaction (qPCR) 
The GeneJET RNA purification kit (Thermo Scientific, Tewksbury, MA) 
was used to extract total RNA from the cells according to the manufacturer’s 
instructions with slight modification.  At the time of harvest, media were removed 
and cells were washed twice with HBSS at room temperature.  Four hundred µL 
of Lysis Buffer supplemented with 20 µL β-mercaptoethanol/mL of Lysis Buffer 
were added.  Cell layers were scraped using sterile cell scrapers and the lysates 
were transferred to 1.5 mL microfuge tubes.  The lysates were then passed 
through a 20-gauge needle on a 1 mL syringe 5 times for complete 
homogenization.  Two hundred forty µL EtOH were added, samples were 
transferred to the GeneJET RNA Purification Columns and centrifuged for 1 
minute at 12,000 x g (Eppendorf 5415R centrifuge).  To remove impurities, 700 
µL of Wash Buffer 1, supplemented with 0.25 mL EtOH/mL, were added to the 
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columns and centrifuged for 1 minute at 12,000 x g.  Two additional washes (600 
µL and then 250 µL, using Wash Buffer 2 supplemented with 1.7 mL EtOH/mL) 
were performed each followed by centrifugation for 1 minute at 12,000 x g.  RNA 
was eluted from the column by centrifugation for 1 minute at 12,000 x g in 30 µL 
nuclease-free water.  The eluent was collected and centrifuged through the 
column an additional time to ensure complete RNA recovery.  RNA was collected 
in the 1.5 mL microfuge tubes provided in the kit and stored at -80°C. 
To assess the quantity and quality of RNA, spectral absorbance at 260 nm 
(A260) and 280 nm (A280) was measured.  Purified RNA (2 µl) was loaded in 
duplicate on the Take3 plate (Take 3 Micro-Volume Plate system; BioTek, 
Winooski, VT) and absorbance measurements were taken (Synergy HT 
microplate reader).  Quantification of RNA (ng/μL) was determined via BioTek’s 
software protocol (178). 
To remove genomic DNA from the purified RNA, a DNase reaction was 
performed following quantification.   RNA (0.5-1 µg) was mixed with molecular 
biology grade water (Cellgro) to a volume of 7.5 µL.  To this, 2.5 µL of DNase mix 
[1 µL 10X DNase I Rxn Buffer (New England Biolabs (NEB), Ipswich, MA), 1 µL 
DNase I ([2000U/mL]; NEB), and 0.5 µL RiboLock RNase Inhibitor (40 U/µL; 
Thermo Scientific)] were added and the reaction was carried out at 37°C for 30 
minutes.  One µL 25 mM EDTA was added and the reactions were heated to 
65°C for 10 minutes to inactivate the DNase. 
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Maxima Universal First Strand cDNA Synthesis (Thermo Scientific) kit was 
used for the reverse transcriptase (RT) PCR to generate cDNA.  Manufacturer’s 
instructions were followed with slight modifications.  Reaction mixtures contained 
5.5 µL DNase-treated RNA (0.25-0.5 µg), 1 µL dNTPs (10 mM), 0.25 µL oligo(dt) 
primer (0.5 μg/μL), 0.25 µL random hexamer primer (0.2 µg/µL), and nuclease-
free water (7 µL).  The reaction was heated to 65°C for 5 minutes followed by 1 
minute at 4°C (Eppendorf Mastercycler PCR Machine model S341).  RT 
synthesis mix [4 µL 5x RT Buffer, 1 µL nuclease-free water, 0.5 µL RiboLock 
RNase Inhibitor (40 U/µL), 0.5 µL Maxima RT (200 U/µL)] was added.  One 
control reaction per experiment received mix with water replacing the RT.  
Reactions were run under the following conditions:  25°C for 10 minutes, 50°C for 
20 minutes, 85°C for 5 minutes and 4°C for 1 minute.  The resulting cDNA was 
diluted 1:6-1:10 with molecular biology grade water and used for qPCR. 
QPCR was performed on the Applied Biosystems 7300 Real Time PCR 
system (ABI, Foster City, CA).  FAM or VIC Taqman probes were purchased 
from ABI (if not commercially available, ABI Primer Express v3.0 was used to 
design primers) (Table 1).  Each reaction using Taqman primer consisted of 
diluted cDNA (2 µL), 2x FastStart Universal Probe Master qPCR mix (Roche Life 
Science, Indianapolis, IN; 10 µl), 20x TaqMan probe (1 µL), and molecular 
biology grade water (7 µL) for a total reaction volume of 20 µL.  Primer  
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Table 1: Taqman qPCR Primers 
Genes* ABI Cat# or designed sequences 
18S Hs99999901_s1 
Acta2 
αSMA 
Rn01759928_g1 
Eln 
Elastin 
Rn01499782_m1 
Gapdh 
GAPDH 
4352338E 
Mmp9 
MMP9 
Rn00579162_m1 
hnMyocd 
hnMyocardin 
Fw: 5’-CATGCTTTACCAATTCCCCACTA-3’ 
Rv: 5’-CATGGCGGGTCAGTTAATCA-3’ 
Probe: 5’- CTCTGTCCAAGTAGCCTT-3’ 
Tlr2 
TLR2  
Rn02133647_s1 
* Indicates gene name followed by nomenclature used for mRNA and 
protein throughout the dissertation 
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sequences used for SYBR green qPCR were obtained from previously published 
experiments (Table 2) and synthesized by Eurofins MWG Operon (Huntsville, 
AL).  Primers were dissolved in molecular biology grade water to a concentration 
of 100 µM and further diluted to 1 µM of both the forward and reverse primers.  
Each reaction using SYBR primers consisted of cDNA (2 µL), 2X FastStart 
Universal SYBR Probe Master qPCR mix (Roche Life Science; 10 µL), 1 µM 
primer mix (2 µl), and molecular biology grade water (6 µL) for a total reaction 
volume of 20 µL. 
For each sample, one reaction measured the target gene of interest while 
an independent reaction was performed to measure 18S rRNA (18S) or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the endogenous 
control used to normalize input levels across multiple samples.  Reactions ran 
under the following conditions:  95°C for 10 minutes, 95°C for 15 seconds 
followed by 60°C for 1 minute for 40 cycles.  When SYBR primers were used, a 
dissociation curve was performed at the end of the PCR to ensure the presence 
of only one amplified product and that no other double stranded DNA dye-binding 
products influenced the observed crossing time (Ct) for those samples.  To 
determine Ct values, 7300 System SDS RQ study software (ABI) was used.  
Data analyses were performed using automatic threshold and baseline settings.  
In cases where expression levels were so low that there was no Ct value after 40 
cycles, data were calculated using a Ct value of 40.  Relative fold changes were 
calculated using the ΔΔCt method as follows.  For normalization of input RNA  
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Table 2: Sybr qPCR Primers 
Rat Genes* Forward Sequence 5’ – 3’ Reverse Sequence 5’-3’ Source 
Cnn 
Calponin H1 ACATCAATTGGCCTACAGATG CAAAGATCTGCCGCTTGGTG (179) 
Cxcl1 
GRO/CINC CATTAATATTTAATGGATGCGTTTCA GCCTACCATCTTTAAACTGCACAAT (180) 
Icam1 
ICAM-1 TGCACGTCCCTGGTGATACTC TGTCAAACGGGAGATGAATGG (181) 
Il1b 
IL-1β TCAGGAAGGCAGTGTCACTCATTG ACACACTAGCAGGTCGTCATCATC (182) 
Il6 
IL-6 CTCATTCTGTCTCGAGCCCA GGCAACTGGCTGGAAGTCTC (183) 
Myocd 
Myocardin CTGTGTGGAGTCCTCAGGTCAAACC GATGTGTTGCGGGCTCTTCAG (179) 
Myh11 
SM-MHC CAAGAGTTCCGGCAACGCTA TCCATCCATGAAGCCTTTGG (179) 
Smtn 
Smoothelin CCAGAGGCTCCTCTAACACTAAGAG TTGGCTCTTGATTTTGGGTTGGCTG (179) 
Pla2g2a 
sPLA2 
GTGACTCATGACTGTTGTTAC CAAAACATTCAGCGGCAGC (184) 
Tagln 
SM22α 
GCATAAGAGGGAGTTCACAGACA GCCTTCCCTTTCTAACTGATGATC (185) 
Vcam1 
Vcam1 ACATGTGCTGCTGGTTGGCTGT GCTCAGCGTCAGTGTGGATGTA (181) 
* Indicates gene name followed by nomenclature used for mRNA and protein throughout 
the dissertation 
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levels, the Ct value of the endogenous control was subtracted from the Ct value 
for the target for each sample (ΔCt).  The median ΔCt value for the experimental 
control triplicate was subtracted from all other ΔCt values in the experiment to 
give ΔΔCt.  Relative quantification (RQ) for each sample was determined using 
the following formula; 2-ΔΔCt.  The average and standard deviation of all replicates 
for each condition was determined and data are expressed as relative mRNA or 
hnRNA expression ± SD (n=3-5). 
Sphingomyelinase Assay 
Cells were cultured under the experimental conditions outlined above and 
neutral sphingomyelinase activity was measured using Amplex Red 
Sphingomyelinase Assay Kit (Invitrogen) according to the manufacturer’s 
instructions.  Media were removed, cells were washed twice with cold PBS on 
ice, and then scraped in 1x Kit Reaction Buffer (0.5M Tris-HCl pH 7.4, 50 mM 
MgCl2) and frozen at -80°C overnight.  The lysate was thawed on ice, sonicated 
twice on ice for 5 seconds each and centrifuged (Eppendorf 5415R) at 3,000 x g 
for 10 minutes at 4°C.  The supernatants (100 µL) were retained and transferred 
to a 96-well black plate.  Positive controls included sphingomyelinase (0.04 
U/mL; 100 µL) and H2O2 (10 µM; 100 µL) solutions while 1x Reaction Buffer (100 
µL) was the negative control.  Each reaction was initiated by adding 100 µL of 
Amplex Red reaction mix (100 µM Amplex Red, 2 U/mL horseradish peroxidase 
(HRP), 0.2 U/mL choline oxidase, 8 U/mL alkaline phosphatase, and 0.5 mM 
sphingomyelin) to each well.  Amplex Red fluorescence was then measured 
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every minute for 1 hour at 37°C with an excitation wavelength of 530 nm and 
emission at 590 nm (Synergy HT micro-plate reader).  Background fluorescence 
was corrected for at each point by subtracting the values derived from the 
negative control.  Sphingomyelinase activity was calculated as the relative 
fluorescence emission units (mRFU) during the linear range of the enzyme 
reaction (i.e. mRFU/minute).  Total protein concentration in the lysates was also 
determined as previously described and used to normalize enzyme activity.   
Data are expressed as mRFU/minute/µg protein) ± SD (n=3).   
Cell Viability Assay 
Cell viability was measured using the MTT Cell Proliferation Assay 
(American Type Culture Collection, Manassas, VA) according to the 
manufacturer’s instructions.  MTT reagent (10 µL) was added to each well.  
Media only wells also received MTT reagent to serve as a blank control for 
background.  Cells were then cultured with the MTT reagent for 4 hours, at which 
time Detergent Reagent (100 µl) was added to each well and then incubated at 
room temperature overnight in the dark.  Absorbance at 570 nm and 670 nm was 
determined (Synergy HT micro-plate reader).  Background correction was 
performed by subtracting the blank 570 and 670 nm absorbance from each 
sample.  The background-corrected reference absorbance (670 nm) was then 
subtracted from the background-corrected absorbance at 570 nm for each 
sample, yielding absorbance values indicative of cell viability, i.e. lower values 
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represent less viable cells whereas higher values represent more viable cells.  
Data are expressed as average cell viability (fold control) ± SD (n=5). 
Western blot analysis 
Cells were placed on ice, media were removed and cells were washed 2 
times with cold PBS.  Whole cell proteins were extracted by adding cold lysis 
buffer [1% Triton X-100, 0.15 M NaCl, 0.01 M Tris pH 7.5, 1 mM EDTA pH 7.5, 1 
mM ethylene glycol tetraacetic acid (EGTA) pH 9.0, 0.5% NP-40] supplemented 
with 1x cOmplete, Mini EDTA-free Protease Inhibitor Cocktail,  and 1x 
PhosSTOP Phosphatase Inhibitor Cocktail (Roche Life Science).  Cells were 
scraped and transferred to pre-chilled microfuge tubes.  Extracts were incubated 
on ice for 20 minutes and inverted every 5 minutes.  Lysates were frozen at -
80°C for 24 hours, thawed on ice and centrifuged (Eppendorf 5415R) at 12,000 x 
g for 10 minutes at 4°C.  The resulting supernatants were removed and 
transferred to new pre-chilled microfuge tubes and cellular debris was discarded.  
Purified protein was stored at -80°C.  For differential extraction of nuclear and 
cytoplasmic proteins, the NE-PER kit (Life Technologies) was used according to 
the manufacturer’s instructions.  Cold CER I supplemented with 1x Halt Protease 
Inhibitor Cocktail (Thermo Scientific) was added and cells were scraped and 
transferred to pre-chilled microfuge tubes.  This cell suspension was then 
vortexed for 15 seconds and incubated on ice for 10 minutes.  Cold CER II was 
added and the samples were vortexed for 5 seconds, incubated on ice for 1 
minute, vortexed for another 5 seconds, and centrifuged at 16,000 x g for 5 
41 
minutes at 4°C.  The resulting supernatants, containing the cytoplasmic proteins, 
were removed and transferred to new pre-chilled microfuge tubes.  The pellet 
was resuspended in cold NER and vortexed for 15 seconds.  The samples were 
placed on ice for 40 minutes (vortexing for 15 seconds every 10 minutes), and 
centrifuged at 16,000 x g for 10 minutes at 4°C.  The resulting supernatants 
containing the nuclear proteins were removed and transferred to new pre-chilled 
microfuge tubes.  Purified nuclear and cytoplasmic proteins were stored at -80°C. 
Protein concentration was measured using the BCA Protein Assay Kit 
(Pierce, Rockford, IL) according to the manufacturer’s instructions.  A standard 
curve was prepared using BSA.  Duplicate samples were diluted 1:1 with water to 
a final volume of 10 µL.  One hundred µL of the working reagent (50 parts BCA 
reagent A:1 part BCA reagent B) were added and the reaction was incubated for 
30 minutes at 37°C.  Absorbance at 562 nm (Synergy HT microplate reader) was 
measured and unknown protein concentrations determined by comparing to the 
standard curve.   
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), equivalent amounts of protein (0.75-30 µg) were denatured for 10 
minutes at 70°C in NuPAGE LDS Sample Buffer (Invitrogen) supplemented with 
NuPAGE Reducing Agent (Invitrogen).  Denatured samples were loaded onto 
NuPAGE Novex Bis-tris 4%-12% gels in 1x NuPAGE LDS running buffer 
(Invitrogen).  Novex Sharp pre-stained ladder (Invitrogen; 5 µL) was run to 
estimate size of proteins.  Electrophoresis was carried out at 75 V for 20-30 
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minutes followed by 150 V for approximately 1.5 hours until the dye-front ran off 
the gel.  Following electrophoresis, proteins were transferred to 0.45 µm 
nitrocellulose membranes (Biorad, Hercules, CA) in 1x NuPAGE Transfer Buffer 
(Invitrogen) with 10% methanol overnight at 35 V at 4°C.  Protein loading was 
visualized by incubating the membrane with Ponceau S (Sigma) for 30 to 60 
seconds at room temperature and washing the membrane 3 times for 10 minutes 
each with TBS + Tween (TBST; 150 mM NaCl, 50 mM Tris pH 7.4 and 0.1% 
Tween-20).  Blots probed for phospho-proteins were blocked in 5% BSA in TBST 
for 1 hour at room temperature.  All other blots were blocked in 5% Western Blot 
Grade-, Non-Fat Milk (Lab Scientific, Highlands, NJ) in TBST for 1 hour at room 
temperature.  Blots were probed with the antibody diluted in its blocking buffer for 
either 2 hours at room temperature or overnight at 4°C depending on the 
antibody used.  Primary antibodies used included mouse anti-αSMA (Sigma 
A2547, 1:2,500 dilution in 5% milk), rabbit anti-SM22α (Abcam ab14106, 1:5,000 
dilution in 5% milk), goat anti-myocardin (Santa Cruz Biotechnology (SCBT) SC-
21561, 1:4,000 dilution in 5% milk), mouse anti-pAkt(Ser473) (Cell Signaling 
#4051, 1:2,000 dilution in 5% BSA) rabbit anti-Akt (Cell Signaling #9272, 1:2,000 
dilution in 5% BSA) and rabbit anti-GAPDH (Sigma G9545, 1:10,000 dilution in 
5% milk).  Blots were washed 3 times in TBST for 10 minutes each followed by 
incubation for 1 hour at room temperature with either anti-rabbit IgG-HRP, anti-
mouse IgG-HRP, anti-goat IgG-HRP (SCBT) (all at a 1:5,000 dilution in 5% milk-
TBST) depending on the primary antibody.  Blots were then washed 3 times with 
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TBST for 10 minutes each and incubated with either enhanced 
chemiluminescence (ECL) Western Blotting Substrate (Pierce), SuperSignal 
Dura Extended Duration Substrate (Pierce) or SuperSignal West Femto 
Maximum Sensitivity Substrate (Pierce) following the manufacturer’s instructions.  
Blots were imaged using the Bio-Rad Chemidoc imaging system using the 
chemiluminescent hi-resolution protocol.  To reprobe, ECL was removed with 
TBST and membranes were stripped with Restore Plus Stripping Buffer (Pierce) 
for 15 minutes at 37°C.  Blots were then washed extensively to remove the 
stripping buffer (2 washes in TBST for 5 minutes each followed by 3 washes for 
10 minutes each).  Stripped blots were reprobed following the procedure 
described above.  
For some experiments, triplicate samples were quantified using the Image 
Lab software v4.0 (Bio-Rad).  Volume boxes were defined for each sample using 
local background subtraction method.  Protein volume was normalized to 
GAPDH volume for each sample.  To generate fold control values, samples were 
divided by the normalized volume of the median control replicate at their 
respective time points.  The data are expressed as average protein/GAPDH (fold 
control) ± SD (n=3). 
Transient transfection and luciferase assays 
Cells were transiently transfected with several promoter constructs driving 
luciferase expression.  A construct containing 216 bp of the rat elastin promoter 
driving luciferase, referred to as 216 Eln-luc was kindly provided by Celeste Rich 
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of Boston University School of Medicine.  A construct containing the -1054 to 
+2696 fragment of the mouse αSMA promoter and first intron driving luciferase in 
the pGL4.10[luc2] (Promega, Madison, WI) vector, referred to as αSMA-luc and a 
construct containing the -441 to +41 fragment of the mouse SM22α promoter 
driving luciferase in the pGL4.10[luc2] vector, referred to as SM22α-luc were 
kindly provided by Dr. Matthew Layne of Boston University School of Medicine.  
Constructs expressing myocardin SMC-isoform, MRTF-A and MRTF-B driven 
from the pFLAG-CMV vector (Sigma), used for reporter rescue experiments, 
were also a kind gift from Dr. Layne (186).   
Cultures were co-transfected with the reporter construct, pRL-CMV-Renilla 
(Promega) (for normalization of transfection efficiency) and, if applicable, 
expression constructs. When the cells were approximately 70% confluent, 
transfections were performed using Polyfect (Qiagen, Valencia, CA) following the 
manufacturer’s instructions.  Media were removed and replaced with fresh 
DMEM containing 10% FBS (100 µL/96-well or 500 µL/24-well).  Plasmid DNA 
was first mixed with DMEM at room temperature (luciferase plasmids, 50 ng/96-
well or 300 ng/24-well; Renilla plasmid, 10 ng/96-well or 50 ng/24-well; 
expression constructs, 1 ng-25 ng/24-well).  Empty vector, pCMV, was added to 
keep total DNA constant across the experiment.  Polyfect, (2.5 µL/µg DNA) was 
mixed with the DNA and incubated at room temperature for 5 minutes to form 
complexes, which were then added (10 µL/96-well or 100 µL/24-well) to the cells.  
After 24 hours, transfection media were removed, cells were washed twice with 
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warm HBSS, and DMEM containing 10% FBS was added.  After an additional 24 
hours, media were removed and the experiment was started under experimental 
conditions listed above.  Firefly and Renilla luciferase activities were measured 
using the Dual-luciferase Reporter Assay Kit (Promega) according to the 
manufacturer’s instructions.  Cells were harvested by removing the media on ice, 
washing twice with cold PBS and lysing in 1x Passive Lysis Buffer.  Lysates were 
frozen (-80°C; at least overnight), at which point the lysates were thawed at room 
temperature and incubated for 15 minutes with rocking.  To read firefly and 
Renilla luciferase activities, lysates (20 µl) were transferred to a 96-well white 
plate (Corning) and read using a program per manufacturer’s instructions on the 
Synergy HT microplate reader.  Data are expressed as luciferase/Renilla ± SD 
(n=3-6). 
Statistics 
Two-tailed unpaired Student’s t-test was used to compare 2 samples.  For 
comparisons of multiple samples with only 1 variable, one-way analysis of 
variance (ANOVA) with Bonferroni post-hoc analysis was used to determine 
statistically significant differences.  Two-way ANOVA was used to make 
comparisons of data with multiple samples and variables.  Statistically significant 
differences of relevant comparisons were determined by Bonferroni post-hoc 
analysis.  Modified Thompson Tau test was used to remove outliers in sample 
sets with n ≥ 5 using an α of 0.05.  Statistically significant differences were 
considered when p<0.05. 
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RESULTS 
Research goals 
Atherosclerosis develops as the result of chronic inflammation within the 
vasculature leading to formation of intimal lesions marked by the accumulation of 
lipids, ECM, macrophages, and SMCs (2,3,35,36).  SMCs are important 
contributors to the disease process and the atherogenic changes to SMCs 
occurring within the lesion include dysregulation of lipid homeostasis and 
phenotypic modulation from the normal contractile state.  Identifying pro-
atherogenic processes that occur in SMCs in response to inflammatory stimuli is 
important to advance disease understanding.  These types of findings may 
potentially identify new avenues for therapeutic approaches to control the 
disease.   
SAA is an inflammatory reactant whose chronic expression has been 
associated with atherosclerosis (116).  Its role in atherosclerosis, in particular the 
effect of SAA localized within lesions on SMCs, remains unknown.  The goal of 
this research was to identify effects of SAA on vascular SMCs by studying the 
effects of lipid-free SAA (representative of SAA expressed in lesions) on cultured 
aortic SMCs.  It was hypothesized that SAA induces cholesterol transport from 
the plasma membrane to the ER and, in addition, that SAA promotes the loss of 
the differentiated contractile phenotype.  As TLR2 was previously demonstrated 
as an SAA receptor (149), it was also hypothesized as the potential receptor 
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mediating these effects.  The impact of TLR2 on immune cells during 
atherosclerosis is well documented (187–190), however how activation of this 
receptor may impact aortic SMCs was previously unknown.   
Together, the studies uncovered novel effects of inflammatory signals on 
vascular SMCs.  Importantly, new TLR2-mediated effects on cells of the vessel 
wall were demonstrated.  SAA was identified as an endogenous ligand that may 
activate TLR2 atherosclerosis, contributing to atherosclerosis. 
Trafficking of endogenous SMC cholesterol: a role for SAA and IL-1β  
SAA traffics cholesterol to the ER 
Previous work in our lab showed that SAA increases expression of the 
Pla2g2a gene leading to increased activity of its protein product sPLA2 (135), 
which is a phospholipase that cleaves fatty acids at the sn-2 position, resulting in 
the release of arachidonic acid and lysophospholipids (69).  Arachidonic acid 
activates sphingomyelinase (191) and sphingomyelinase-mediated degradation 
of plasma membrane-associated sphingomyelin releases free cholesterol which 
is trafficked to the ER (192).  Therefore, it was hypothesized that the SAA-
mediated increase in SMC sPLA2 activates sphingomyelinase, which liberates 
sphingomyelin-associated cholesterol at the plasma membrane, freeing it for 
movement to the ER (193). 
To test this hypothesis, neonatal rat aortic SMCs were treated with SAA 
and movement of cholesterol to the ER was monitored.  Since free cholesterol is 
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only esterified in the ER (58), esterification of cholesterol is used as a measure of 
the arrival of cholesterol in the ER.  To monitor cholesterol esterification, 
incorporation of [14C]oleic acid into [14C]cholesteryl oleate was measured.  In 
support of the hypothesis, significantly more [14C]cholesteryl oleate accumulated 
in SMCs treated with SAA (2 µM) for 24 hours than in control-treated cells 
(Figure 1), demonstrating an increased movement of cholesterol to the ER upon 
SAA treatment.  
SAA decreases plasma membrane cholesterol 
As stated above, the hypothesis is that plasma membrane cholesterol is 
trafficked to the ER upon SAA treatment.  Cholesterol trafficking (Figure 1) was 
performed in media containing serum deprived of lipids, demonstrating that 
endogenous cholesterol was trafficked.  Furthermore, other results support the 
role of endogenous cholesterol by demonstrating the movement of 
[3H]cholesterol to the ER as measured by its conversion to [3H]cholesteryl oleate 
(193).  To determine if the cholesterol involved in the SAA-mediated trafficking to 
the ER originated from the plasma membrane, SMCs were prelabeled with 
[3H]cholesterol then treated with (or without) SAA for 7 days, at which time 
plasma membrane-associated [3H]cholesterol was determined.  The cholesterol-
oxidase sensitive pool of cholesterol, i.e. the pool of [3H]cholesterol converted to 
[3H]cholestenone by the enzyme, represents plasma membrane cholesterol since 
the cholesterol oxidase can only access cholesterol in this compartment (194).  
Significantly less [3H]cholesterol was converted to  
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Figure 1: SAA induces cholesterol trafficking to the ER.  
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[3H]cholestenone in SAA-treated cells demonstrating that there was less plasma 
membrane cholesterol in these cells compared to control-treated cells (Figure 2).  
These data support the hypothesis that SAA mediates trafficking of plasma 
membrane cholesterol to the ER.  
SAA-mediated cholesterol trafficking is cPLA2 dependent 
Additional experiments from our laboratory showed that activation of 
sPLA2 is critical for SAA-mediated cholesterol trafficking (193).  As others have 
shown that cPLA2 activity can impact sPLA2 expression in rat fibroblastic 3Y1 
cells (195), the role of cPLA2 in SAA-mediated cholesterol trafficking was 
examined.  [14C]cholesteryl oleate accumulation was measured in cells treated 
with or without SAA in the presence or absence of the cPLA2 inhibitor (196) 
AACOCF3 (Figure 3A).  Interestingly, accumulation of cholesterol in the ER in 
SAA-treated cells was blocked in the presence of AACOCF3.  Furthermore, 
inhibition of cPLA2 activity significantly blunted SAA-induced expression of sPLA2 
mRNA (Figure 3B).  Together, these data show that cPLA2 activity is necessary 
for the SAA-induced activation of sPLA2 and cholesterol trafficking.   
SAA activates sphingomyelinase 
Neutral sphingomyelinase activity was measured in SMCs treated with or 
without SAA to investigate whether sphingomyelin-associated cholesterol at the  
plasma membrane is liberated for movement to the ER following the degradation 
of sphingomyelin by sphingomyelinase at the plasma membrane.  Compared to  
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Figure 2: SAA decreases plasma membrane cholesterol.  
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Figure 3: SAA-mediated cholesterol trafficking cPLA2 dependent. 
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control-treated cells, neutral sphingomyelinase activity increased significantly in 
cells treated with SAA for both 3 and 7 days (Figure 4).  Additional studies from 
our laboratory demonstrated that cholesterol trafficking was completely blocked 
in cells treated with 3-OMe sphingomyelin to inhibit sphingomyelinase and that 
supplementing the cultures with sphingomyelin prevented SAA-induced 
cholesterol trafficking (193).  Overall, these data demonstrate that SAA activates 
sphingomyelinase, which is critical for the trafficking of SMC cholesterol to the 
ER mediated by SAA. 
IL-1β induces cholesterol trafficking to the ER 
Other inflammatory mediators were studied to determine if cholesterol 
trafficking to the ER was a general inflammatory response or specific to acute 
phase SAA.  Previously, our laboratory showed that IL-1β, similar to SAA, 
induces expression of sPLA2 mRNA (135).  Interestingly, sPLA2 expression was 
not significantly induced by either TNF-α or IFN-γ (Figure 5A).  Moreover, IL-1β, 
which activated sPLA2, also induced cholesterol trafficking to the ER, while 
mediators that did not activate sPLA2, TNF-α and IFN-γ, did not increase 
cholesterol esterification (Figure 5B).  These data show, in addition with other 
data above, that SAA and IL-1β induce cholesterol movement to the ER and that 
this is not a general consequence of treatment with all inflammatory mediators. 
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Figure 4: SAA activates neutral sphingomyelinase. 
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Figure 5:. IL-1β induces cholesterol trafficking to the ER. 
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Lipid-bound SAA does not induce cholesterol trafficking 
SAA readily associates with HDL when combined in vitro (123). 
Previously, our laboratory reported that lipid-bound SAA, associated with HDL, is 
unable to activate sPLA2 expression (135) (Figure 6A).  Consistent with the 
hypothesized role for sPLA2 in cholesterol trafficking, [14C]cholesteryl oleate 
accumulation was completely blocked in SAA-treated cells in the presence of 
HDL (Figure 6B).      
Lysosomal inhibitors do not cause overt cell toxicity 
SAA-mediated trafficking occurs via the endolysosomal system, as 
[14C]cholesteryl oleate failed to accumulate after 24 hours in SAA-treated cells 
that were pre-treated with the lysosome inhibitors chloroquine, bafilomycin A1 or 
U18666A (5).  However, cell toxicity of these inhibitors after a prolonged 
treatment was a concern.  To address this, the MTT assay was used to 
investigate the effect of these compounds on cell viability in SMCs treated in the 
absence or presence of SAA and either chloroquine or U18666A for 24 hours 
(Figure 7).  No decrease in cell number was seen in any combination of inhibitor 
or treatment after 24 hours.  In fact, cells treated with SAA, with no inhibitor or 
with U1866A, had slightly increased number of cells.    
SAA and TLR2 promote phenotypic modulation of SMCs 
Atherosclerosis is a progressive disease in which endothelial dysfunction 
induces an inflammatory response within the intimal layer of the vasculature,  
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Figure 6: HDL-associated SAA does not induce cholesterol trafficking to the ER.  
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Figure 7: Lysosome inhibitors do not cause cell toxicity.  
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leading to recruitment of platelets, monocytes and T lymphocytes that in-turn 
generate an inflammatory cascade known to drive disease pathology (2,36,197–
199).  In addition, SMCs migrate from the medial layer of the vessel to the intima 
where they proliferate and deposit ECM, contributing to formation of the 
atherosclerotic plaque (2).  The normal, differentiated SMC phenotype, marked 
by the expression of SMC-specific contractile proteins, is lost and instead 
transitions to both synthetic and inflammatory phenotypes have been described 
(32).  While functional differences between these phenotype have been defined 
(200), the molecular mechanism controlling SMC phenotype switching in the 
context of inflammation and atherosclerosis remains incompletely understood. 
The effects of SAA on SMC function as it relates to atherogenesis has 
been the focus of our laboratory for many years.  Most recently, others in the 
laboratory demonstrated that SAA impacts ECM gene expression (137), such 
that Eln gene expression is repressed while Mmp9 gene expression is activated, 
contributing to decreased elastin matrix deposition.  In addition, data from a pilot 
microarray performed on SMCs treated with SAA for 1 or 7 days suggested that 
expression of contractile SMC markers, most notably Acta2 and Myh11, were 
repressed by SAA (data not shown).   
The impact of SAA on SMC phenotype is unknown and therefore it was 
hypothesized that SAA promotes phenotypic modulation of SMCs, characterized 
by the loss of the contractile phenotype and the acquisition of inflammatory 
characteristics.  Moreover, many receptors for SAA have been reported 
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(143,147,201–205).  Of particular interest is a report demonstrating that SAA is a 
functional ligand for TLR2 (149).  Most recently, our laboratory showed that SAA 
activates MMP9 in a TLR2-dependent manner (137) but the role of TLR2 on 
SMC-specific contractile genes is unknown.  Therefore, the current hypothesis 
was expanded such that the mechanism for SAA-mediated phenotypic 
modulation is via activation of TLR2. 
SAA induces loss of SMC contractile phenotype 
To investigate the effect of SAA on SMC expression of contractile 
markers, gene expression of several SMC-specific markers was measured in 
SMCs treated with SAA for 24 hours.  SAA treatment led to a significant down-
regulation in mRNA expression of the Acta2, Tagln, Myh11, Cnn1, and Smtn 
genes, suggesting that SAA promotes loss of the contractile phenotype (Figure 
8).  Western blot analysis of αSMA and SM22α (protein products of the Acta2 
and Tagln genes, respectively) was performed to determine if the loss of mRNA 
expression was also realized at the protein level.  Interestingly, although levels of 
expression of Acta2 and Tagln mRNA were down-regulated (Figure 8), protein 
expression of αSMA and SM22α did not decrease after 24 hours of SAA 
treatment (Figure 9A).  To determine the effect of chronic SAA exposure on 
these proteins, Western blot analysis was performed on SMCs treated with SAA 
(2 µM) for 4, 7, or 14 days.  A representative blot is shown in (Figure 9B).  
Quantitation of triplicates shows that expression of αSMA protein was 
significantly repressed by SAA after 4 days (37%) and that this repression  
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Figure 8: SAA down-regulates SMC contractile genes.  
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Figure 9: SAA down-regulates contractile SMC marker proteins  
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persisted through both 7 (55%) and 14 days (60%) of SAA treatment (Figure 
9C).  SM22α was repressed by SAA after 7 days (35%) of treatment and this 
repression continued through to 14 days (37%) (Figure 9D).  Overall, these data 
indicate that SAA induces a loss of SMC contractile phenotype as evidence by a 
decrease in expression of SMC-specific markers required for contraction.  
TLR2 promotes the loss of SMC contractile phenotype 
As discussed earlier, TLR2 is a receptor for SAA (149).  To determine a 
potential role for TLR2 on SMC phenotype, expression of SMC contractile 
markers was studied in cells treated with TLR2 ligands.  Interestingly, levels of 
expression of mRNA for the contractile marker genes Acta2, Tagln, Myh11, 
Cnn1, and Smtn were significantly down-regulated following 24 hours of 
treatment with either of two synthetic TLR2 agonists, FSL or Pam (Figure 10).  In 
addition, Western blot analysis for αSMA and SM22α was performed on SMCs 
treated with either FSL or Pam for 4, 7, or 14 days to determine if protein 
expression of these contractile proteins was also down-regulated.  A 
representative blot is shown in (Figure 11A).  Quantitation of triplicates shows 
that expression of αSMA protein was significantly repressed as early as 4 days of 
either FSL (45%) or Pam (19%) treatment, and continued through both 7 and 14 
days of treatment (Figure 11B).  Likewise, SM22α was significantly repressed by 
both FSL (39%) and Pam (18%) after 4 days and this continued through to 14 
days of treatment (Figure 11C).  Similar to SAA, activation of TLR2 by these  
  
64 
Figure 10: TLR2 activation down-regulates SMC contractile genes. 
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Figure 11: TLR2 activation down-regulates contractile SMC marker proteins. 
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TLR2 ligands repressed the contractile phenotype of SMCs as evidenced by the 
loss of contractile markers.   
SAA-mediated repression of the contractile phenotype is TLR2-dependent 
To test the hypothesis that SAA promotes a phenotypic switch from the 
contractile state through the activation of TLR2, loss-of-function studies were 
performed in SMCs in which TLR2 expression was knocked down via siRNA and 
the ability of SAA to repress contractile marker expression was analyzed.  
Efficient knockdown of Tlr2 mRNA was achieved in SMCs transfected with siRNA 
targeting TLR2 (Figure 12).  In this experiment Tlr2 mRNA was knocked down 
by 80%, which is in line with subsequent experiments shown where typical 
knockdown of Tlr2 mRNA was between 75-90%.  Consistent with the work of 
others (206), TLR2 stimulation promoted an increase in Tlr2 mRNA expression 
which was observed with SAA, as well as the TLR2 ligand FSL.  In cells in which 
TLR2 expression was knocked down, Tlr2 mRNA expression was up-regulated 
approximately 2 fold in the presence of SAA and FSL.  While expression did not 
reach the same levels as in the cells treated with the control siRNA, Tlr2 mRNA 
was still higher in the treated knockdown compared to untreated cells.   
To evaluate the role of TLR2 in SAA-mediated SMC contractile phenotype 
repression, mRNA expression of contractile markers was measured in SAA- and 
FSL-treated SMCs in which TLR2 was knocked down (Figure 13).  Expectedly, 
FSL-mediated repression of both Acta2 and Myh11 was significantly abrogated in  
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Figure 12: TLR2 knockdown via siRNA.  
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Figure 13: SAA-mediated repression of contractile phenotype is TLR2-dependent   
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cells transfected with siTLR2 compared to siCtl cells.  While not significant, FSL-
induced down-regulation of Cnn1 trended towards rescue with TLR2 knockdown.   
SAA-mediated repression of all 3 contractile markers was significantly rescued 
by TLR2 knockdown, showing that SAA-mediated repression of SMC contractile 
genes is TLR2-dependent. 
SAA and TLR2 activation promote an inflammatory phenotype 
Phenotypic modulation of SMCs from the contractile state to a pro-
inflammatory state is well described (32).  Our laboratory has shown that SAA 
promotes inflammatory responses in SMCs, such as activation of sPLA2 (135) 
and MMP9 (137).  Therefore, the role of SAA and TLR2 activation on 
inflammatory SMC gene expression was investigated in SMCs treated with SAA, 
FSL or Pam for 24 hours.  Expression levels of Il1b, Il6, and Cxcl1 (the rat 
homologue of IL-8) (Figure 14A), as well as Vcam1 and Icam1 (Figure 14B) 
were significantly up-regulated in SMCs treated with SAA and the TLR2 agonists.  
To determine if the inflammatory phenotype activated by SAA is TLR2-
dependent, knockdown experiments investigating the ability of SAA to promote 
expression of inflammatory markers were performed.  Both SAA- and FSL-
mediated activation of Il6 and Cxcl1 mRNA was significantly blunted in 
knockdown cells compared to control cells (Figure 15A).  Interestingly, Vcam1 
mRNA activation was only blocked by TLR2 knockdown in cells treated with 
TLR2 ligands (FSL or Pam), while loss of TLR2 had little effect on the SAA-
mediated up-regulation of Vcam1 expression (Figure 15B).   
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Figure 14: SAA and TLR2 induce an inflammatory gene profile  
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Figure 15: SAA-induced inflammatory phenotype is TLR2-dependent.  
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SAA-1 induces SMC phenotype modulation 
The recombinant SAA used in these experiments was produced as a 
hybrid of 2 SAA isoforms.  The amino acid sequence of this molecule is 
predominantly that of human SAA1α however 2 amino acids have been 
substituted for their SAA2β counterparts, asparagine for aspartic acid at position 
60 and arginine for histidine at position 71.  Others have reported that this hybrid 
SAA may exert effects that are not shared with that of physiologically-relevant 
SAA1α (SAA-1) (207,208).  Therefore, experiments were performed to compare 
the effects of both preparations in our system.  Unlike the hybrid molecule, SAA-
1 failed to activate Mmp9 mRNA expression (Figure 16), a gene previously 
shown to be activated by the hybrid SAA preparation (137).  Upon discussion 
with the manufacturer of these recombinant proteins, it was discovered that the 
purification procedure used for SAA-1 differed from that of the hybrid SAA.  
Therefore, to test if this purification difference was responsible for the lack of 
efficacy of the SAA-1 molecule, SMCs were treated with hybrid SAA or with SAA-
1, either prepared with the original method [SAA-1 (Old)] or by the same method 
as that used for the hybrid [SAA-1 (New)].  Cells were treated for 24 hours and 
mRNA expression of various genes was measured.  As shown above, hybrid 
SAA activated Mmp9 mRNA expression and interestingly, SAA-1 also activated 
Mmp9 mRNA expression only when purified in the same manner as the hybrid 
(Figure 17A).  Measurements of mRNA expression of other genes demonstrated 
that SAA and SAA-1 (New) but not SAA-1 (Old) activated Il6, Il1b,  
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Figure 16: SAA-1 does not activate Mmp9 expression.  
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Figure 17: SAA-1 impacts SMC gene expression identical to hybrid SAA.  
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and Cxcl1 expression (Figure 17B).  Moreover, SAA and SAA-1 (New) similarly 
repressed expression of SMC contractile markers including Acta2, Tagln, and 
Myh11; although SAA-1 (Old) also repressed Acta2 and Myh11, this effect was 
significantly less than that of the hybrid or SAA-1 (New) (Figure 17C).  
Interestingly, SAA-1 repressed Eln expression regardless of the purification used 
(Figure 17D).  These data demonstrate that SAA-1 effects on SMC function are 
virtually identical to those of the hybrid SAA molecule.  Furthermore, SAA-1 
purified differently than the hybrid molecule that has possibly been the subject of 
previous reports does not mirror the effects of hybrid SAA. 
HDL-associated SAA does not promote phenotype modulation 
SAA functions can differ depending on whether or not it is lipid-free or 
bound to HDL (209).  Experiments were performed to determine the effect of 
lipid-bound (HDL) SAA in SAA-mediated SMC gene expression changes.  SMCs 
were treated with SAA or FSL prepared in the absence or presence of HDL for 
24 hours and expression of various genes was measured via qPCR.  The SAA-
mediated effects on Acta2 (Figure 18A), inflammatory interleukins (Figure 18B), 
and Vcam1 (Figure 18C) were completely blocked by HDL association.  FSL-
mediated effects were unchanged by HDL.    
Contractile markers are repressed transcriptionally 
As shown above (Figures 8 & 11), SAA and TLR2 activation down-
regulate mRNA expression of various contractile genes in SMCs.  To study if this  
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Figure 18: HDL blocks SAA-mediated SMC phenotype modulation.  
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occurs at the level of transcription, promoter activity of αSMA was analyzed in 
SMCs treated with either SAA or TLR2 ligands for 24 hours (Figure 19).  Activity 
of the αSMA-luc promoter construct was significantly repressed by SAA as well 
as the TLR2 agonists, FSL and Pam.  These data suggest that contractile marker 
down-regulation, at least for αSMA, occurs at the level of transcription resulting 
via decreased promoter activity.   
SAA and TLR2 activation repress myocardin expression 
Expression of SMC-specific contractile genes is largely driven by SRF-
dependent transcription (12,210,211).  The ability of the SRF co-activator, 
myocardin, to complex with the SRF machinery is critical for this mechanism of 
transcription (212).  Myocardin expression was analyzed to determine its role in 
SAA- and TLR2-mediated SMC phenotype modulation.  SMCs were treated with 
SAA, FSL, or Pam for various lengths of time and expression of Myocd mRNA 
was measured (Figure 20A).  Myocd mRNA was significantly down-regulated by 
SAA after 8 hours and this effect persisted through to 24 hours.  Similarly, FSL-
mediated repression of Myocd mRNA was detected in as little as 4 hours and 
also persisted throughout the time course.  To determine if altered gene 
transcription is the level at which Myocd mRNA is regulated, heteronuclear (hn) 
Myocd RNA was measured over the same time course using primers designed to 
recognize a region of intron 1 in the nascent pre-mRNA transcript of Myocd.  
Similarly to the mRNA, Myocd hnRNA was  
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Figure 19: SAA and TLR2 activation repress αSMA promoter activity.  
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Figure 20: SAA and TLR2 repress Myocd expression.  
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significantly down-regulated by both SAA and FSL, suggesting that expression of 
myocardin is repressed at the level of gene transcription (Figure 20B).   
To further study myocardin down-regulation by SAA and TLR2 activation, 
protein analysis was conducted by Western blotting in SMCs treated with SAA or 
FSL for 8, 12, or 24 hours (Figure 21).  SAA- and FSL-mediated down-regulation 
of myocardin was detected after 12 and 8 hours of treatment respectively which 
persisted through to 24 hours.  Taken together, these data show that SAA and 
TLR2 activation repress Myocd gene transcription resulting in the loss of 
expression of its mRNA and protein.   
Contractile phenotype repression is myocardin-dependent 
Myocardin is an important transcriptional co-activator that drives 
expression of SMC contractile markers (25) and the studies above show that 
expression of these markers is largely lost in response to SAA and FSL.  
Therefore, it was hypothesized that the loss of the contractile phenotype 
mediated by SAA and TLR2 is dependent on the loss of myocardin.  To address 
this, the ability of myocardin to rescue SAA- and TLR2-mediated repression of 
SMC-specific gene promoters was measured.  SMCs were co-transfected with 
the αSMA-luc promoter construct and different doses of a myocardin expression 
vector, and then treated with SAA, FSL, or Pam for 24 hours (Figure 22A).  As 
expected, myocardin activated baseline activity of the αSMA-luc reporter.  
Moreover, expression of myocardin blocked the SAA-mediated down-regulation 
of reporter activity.   
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Figure 21: SAA and TLR2 down-regulate myocardin protein.  
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Figure 22: Myocardin rescues SAA- and TLR2-mediated repression of contractile gene 
promoters.  
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Similar studies were performed to determine the effect of myocardin on 
Tagln promoter activity.  SAA- as well as FSL-mediated repression of the Tagln 
promoter was blocked by overexpression of myocardin (Figure 22B).  Pam-
mediated repression of the Tagln promoter activity did not achieve significance in 
this experiment.  Eln gene expression is not known to be SRF-driven; therefore 
its promoter activity was examined to determine the specificity of the myocardin-
mediated effect.  SAA, FSL, and Pam decreased Eln promoter activity however 
exogenous myocardin had no effect on repression of the promoter by either SAA 
or TLR2 activation (Figure 22C).  Taken together, these data show that loss of 
myocardin expression correlates with loss of SMC-specific contractile gene 
expression.   
Myocardin family members rescue SMC contractile promoter repression 
The myocardin family members, MRTF-A and MRTF-B, are also strong 
co-activators of SRF-mediated transcription (212).  Their ability to rescue SAA-
mediated repression of the SM22α -luc reporter was also examined in preliminary 
studies.  Overexpressing either MRTF-A or MRTF-B rescued SAA-mediated 
down-regulation of the SM22α promoter (Figure 23A).  To further understand the 
potential role of MRTF-A, nuclear localization was analyzed by Western blotting 
in SMCs treated with SAA or TLR2 agonists for 24 hours (Figure 23B).  Results 
from the preliminary experiments showed that nuclear localization of MRTF-A 
was unaffected by either SAA or FSL-treatment.  Overall, these data suggest that 
although the MRTFs can rescue SAA-mediated Tagln promoter repression, their  
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Figure 23: MRTF-A and MRTF-B rescue SM22α promoter repression. 
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involvement seems unlikely in this system due to a lack of change in their 
functional status, at least in the case of MRTF-A.      
TLR2 activates Akt, which is not required for TLR2-mediated SMC phenotype 
modulation 
Determining intracellular signaling events leading from TLR2 activation to 
myocardin repression is important and will contribute additional knowledge 
regarding SMC phenotype modulation in context of inflammation and 
atherosclerosis.   The serine/threonine kinase, Akt has been shown by others to 
function as both a positive and a negative regulator of myocardin expression 
(213–215).  In addition, activation of Akt upon TLR2 stimulation has been shown 
in multiple studies (216–218), however the effect of TLR2 activation on 
myocardin expression is unknown.  Therefore, a role for Akt in TLR2-mediated 
SMC phenotype modulation was assessed by first measuring Akt activation via 
phosphorylation at Ser473, in cells treated with FSL for various periods of time.  
FSL treatment resulted in a rapid phosphorylation of Akt at Ser473 starting at 15 
minutes and continuing throughout the 1 hour time course (Figure 24A).  An 
extended time course revealed that FSL-mediated phosphorylation of Akt 
persisted for 8 hours with pAkt returning to levels in untreated cells by 12 hours 
(Figure 24B).   
To determine the role of Akt activation, if any, on the TLR2-mediated 
repression of myocardin expression, SMCs were treated with or without FSL in 
the presence or absence of the pAkt inhibitor, MK2206 (0, 3, or 6 µM) for 6 or 24  
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Figure 24: TLR2 activation induces Akt phosphorylation. 
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hours and its expression was measured.  MK2206 was effective in inhibiting Akt 
phosphorylation (Figure 25A), however it did not inhibit FSL-mediated repression 
of Myocd mRNA expression (Figure 25B); although repression was not 
significant in some cases, all at least showed a trend towards down-regulation.  
Interestingly, MK2206 did negatively affect expression of Myocd mRNA in 
control-treated SMCs.  Taken together, these data suggest that TLR2-mediated 
repression of myocardin expression occurs independently of the TLR2-induced 
activation of Akt.   
SMC phenotype modulation and cholesterol trafficking occur 
independently 
As demonstrated above (Figure 1), SAA induces trafficking of plasma 
membrane cholesterol to the ER in SMCs and promoted phenotypic modulation 
of SMCs from a contractile state to an inflammatory one (Figures 8,9, & 14), a 
process occurring through activation of TLR2 (Figures 13 & 15).  SMC 
accumulation of cholesterol esters in culture has been demonstrated (219).  
Additionally, cholesterol loading in SMCs was shown to repress contractile 
phenotype as evidence by a decrease in gene expression of many SMC-specific 
contractile markers (220).  Weinert et al. showed that cholesterol-loaded 
lysosome transferred to SMCs from macrophages altered SMC phenotype as 
indicated by the activation of macrophage markers, however SMC-specific 
contractile marker expression was not measured in their study  
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Figure 25: TLR2-mediated repression of myocardin is Akt-independent. 
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(221).  The reports demonstrate a role for cholesterol influx to impact SMC 
phenotype; however they did not investigate the potential impact of intracellular 
cholesterol trafficking on SMC gene expression and phenotype.  Therefore it was 
important to investigate the effect of the observed change in intracellular 
cholesterol homeostasis on SMC phenotype.  
Inhibition of cholesterol trafficking does not impact SMC phenotype modulation 
To determine if TLR2 activation impacts cholesterol trafficking, the 
incorporation of [14C]oleic acid into [14C]cholesteryl oleate was measured.  As we 
showed previously (193) and above (Figure 1), [14C]cholesteryl oleate 
accumulated in cells treated with SAA.  Interestingly, [14C]cholesteryl oleate 
accumulation in FSL- and Pam-treated cells was also evident, demonstrating that 
cholesterol trafficked to the ER via TLR2 activation (Figure 26A).   
As we showed that inhibition of endolysosomal transport blocks SAA-
mediated trafficking of cholesterol to the ER (193), chloroquine was used to 
inhibit cholesterol movement and SAA- and TLR2-mediated SMC gene 
expression was studied.  In the presence of chloroquine, cholesterol transport 
was inhibited in control-treated SMCs and neither SAA, FSL, nor Pam had an 
effect on cholesteryl ester accumulation.  On the other hand, SAA and the TLR2 
ligands significantly repressed Myocd and Acta2 regardless of whether or not 
chloroquine was present (Figure 26B).  Additionally, activation of Il6 or Mmp9 
expression by SAA, FSL or Pam was unaffected by chloroquine.   
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Figure 26: Blocking cholesterol trafficking with chloroquine has no effect on SMC phenotype 
modulation.   
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Together, these data suggest that inhibiting cholesterol trafficking via the 
endolysosomal system has no impact on SAA/TLR2-mediated SMC phenotype 
modulation.   
Sphingomyelinase activation is critical for SAA-mediated cholesterol 
trafficking (Figure 3) (193).  Exogenous addition of sphingomyelin bypasses the 
role of sphingomyelinase by replenishing plasma membrane-associated 
sphingomyelin, thereby inhibiting the release of cholesterol for trafficking to the 
ER (193).  To further study if cholesterol movement is necessary for SMC 
phenotype modulation, additional experiments adding sphingomyelin to inhibit 
cholesterol trafficking were performed while observing SAA- or TLR2-mediated 
SMC gene expression.  As expected, exogenous addition of sphingomyelin (10 
µg/mL) blocked [14C]cholesteryl oleate accumulation in cells treated with SAA, 
FSL, or Pam for 24 hours (Figure 27A).  SAA- and TLR2-mediated repression of 
Myocd and Acta2 and activation of Mmp9, occurred irrespective of exogenous 
addition of sphingomyelin (Figure 27B).  These data show that blocking 
cholesterol trafficking to the ER using sphingomyelin has no effect on the studied 
SAA- or TLR2-induced SMC gene expression changes.   
Finally, SMCs were either loaded with, or depleted of, cholesterol and the 
impact on gene expression assessed.  In this regard, [14C]cholesteryl oleate was 
measured in SMCs treated in the absence or presence of either 
cholesterol:methyl β-cylcodextrin (MβCD) or MβCD for 72 hours, the last 24 
hours of which was without or with SAA.  As expected, adding cholesterol led to  
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Figure 27: Blocking cholesterol trafficking with sphingomyelin has no effect on SMC. 
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a large accumulation of [14C]cholesteryl oleate (Figure 28A).  SAA did not further 
increase accumulation of [14C]cholesteryl oleate under this condition.  
[14C]cholesteryl oleate accumulation, while not significant, was lower in MβCD-
treated cells suggesting successful removal of cholesterol from those cells.  
Again, SAA did not promote cholesterol trafficking under this condition.  
Consistent with the previous two experiments, SAA-mediated repression of 
Myocd or Acta2 occurred regardless of cholesterol addition or removal (Figure 
28B), suggesting that SAA-mediated phenotype modulation occurs 
independently of cellular cholesterol status.   
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Figure 28: Loading or removing cellular cholesterol has no effect on SMC phenotype 
modulation. 
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DISCUSSION 
The studies presented here demonstrate that: 1) SAA and TLR2 mobilize 
cholesterol from the plasma membrane to the ER in SMCs, 2) SAA and TLR2 
promote SMC phenotype modulation from a contractile state to an inflammatory 
one, and 3) the described SMC phenotype modulation occurs independently of 
the cholesterol mobilization (Figure 29).  Cholesterol trafficking is lysosome-, 
sPLA2-, cPLA2-, and sphingomyelinase-dependent.  SAA-/TLR2-mediated SMC 
phenotype modulation involves loss of SMC-specific contractile markers and the 
activated expression of inflammatory genes.  Loss of myocardin expression was 
critical for the repression of the contractile genes and this occurs independently 
of Akt.   
SAA promotes cholesterol trafficking to the ER from the plasma membrane 
Esterification of free cholesterol with fatty acids is mediated by the ACAT 
enzyme whose localization is restricted to the ER.  Therefore, the measurement 
of cholesterol esterification (i.e. the incorporation of [14C]oleic acid into 
[14C]cholesteryl ester) reflects movement of cholesterol to this compartment and 
is commonly used as an assay to monitor cholesterol transport to the ER 
(58,222).  Incorporation of [14C]oleic acid into [14C]cholesteryl ester increased in 
cells treated with SAA, demonstrating enhanced movement of cholesterol to the 
ER (Figure 1).  Since these experiments were performed with serum deficient in 
lipoproteins, it was hypothesized that endogenous cholesterol, specifically 
plasma membrane-derived, is trafficked to ER.  In support of this, our laboratory  
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Figure 29: Model depicting SAA and TLR2 effects on SMC cholesterol trafficking and 
phenotype.  
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showed that cholesterol trafficked to the ER in response to SAA as measured by 
an increased incorporation of cell-associated [3H]cholesterol into [3H]cholesteryl 
ester (193) and that SAA treatment of SMCs resulted in less plasma membrane 
cholesterol (Figure 2).  These data support the hypothesis and demonstrate that 
the cholesterol that arrived in the ER originated from the plasma membrane.   
Previous work in our laboratory also showed that SAA induces the 
activation of sPLA2 via increased mRNA expression of the Pla2g2a gene (135).  
Arachidonic acid, a product of sPLA2 enzyme activity, stimulates the activity of 
sphingomyelinase (191) which stimulates cholesterol transport to the ER 
(192,223).  Results shown above (Figure 4) demonstrated that SAA induced the 
activation of neutral sphingomyelinase.  Furthermore, inhibiting this activity or 
replenishing sphingomyelin blocked SAA-induced cholesterol trafficking (193).  
Taken together, these data showed that SAA-mediated activation of 
sphingomyelinase degraded sphingomyelin at the plasma membrane, which 
liberated cholesterol for trafficking to the ER.  These results identify SAA and 
TLR2 as novel mediators of intracellular cholesterol trafficking within SMCs.  This 
represents a novel mechanism for inflammatory-induced changes in SMC 
function.   
Presumably, sterol regulatory element-binding protein (SREBP) activity 
will be blocked by the increased ER cholesterol as described in detail by Brown 
and Goldstein (54,224).  Indeed, our laboratory has seen that SREBP binding to 
sterol regulatory elements is decreased using a reporter system (data not 
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shown), but the role of ER cholesterol here is still undetermined and warrants 
further investigation.  In addition, our laboratory published that SAA decreases 
SMC lipid biosynthesis (140), however the mechanism of this decrease, as well 
as, the involvement of SREBP in this process remains elusive.  AMP-activated 
protein kinase (AMPK) is an energy sensor that maintains cellular energy 
homeostasis (225,226) and could potentially mediate the decrease in lipid 
synthesis by SAA.  Inhibition, via phosphorylation, of 3-hydroxy-3-methylglutaryl-
CoA reductase and acetyl-CoA carboxylase (ACC) by AMPK reduces cellular 
lipid synthesis (227,228).  In addition, AMPK-mediated phosphorylation of 
SREBP-1c negatively modulates its activity (229).  Preliminary studies showed 
increased phosphorylation of AMPK at Thr172, as well as phosphorylation of 
ACC at Ser79 in response to SAA treatment (data not shown).  These data 
suggest that SAA activates AMPK.  Furthermore, phosphorylation of ACC is a 
possible mechanism whereby SAA mediates a down-regulation of fatty acid 
biosynthesis.  Future studies investigating the dynamics between AMPK, 
cholesterol trafficking, and lipid biosynthesis should be performed to identify the 
impact of the SAA- and TLR2-mediated cholesterol trafficking on SMC function 
In addition, many others have shown that intracellular accumulation of 
lipids induce ER stress (230–232), resulting in the activation of a series of 
adaptive mechanisms, termed the unfolded protein response (UPR), that copes 
with protein-folding alterations (233).  In particular, Feng et al. showed that 
cholesterol trafficking to the ER activated UPR in cholesterol-loaded 
99 
macrophages, resulting in cholesterol-induced apoptosis (230).  Therefore, SAA-
mediated SMC ER cholesterol accumulation may induce ER stress and the UPR.  
Preliminary studies in the laboratory support this in that chronic treatment of 
SMCs with SAA (or a TLR2 agonist) resulted in the up-regulation of multiple UPR 
marker genes (Hspa5[BIP/GRP78], Atf6[ATF6], Ddit3[CHOP]) (234) (data not 
shown).  These results suggest that SMC cholesterol trafficking to the ER 
activate an ER stress response which may have downstream signaling, protein 
folding, and/or cell viability consequences that remain unknown. 
SAA-mediated cholesterol trafficking requires cPLA2 
Activity of cPLA2 was required for both the cholesterol trafficking (Figure 
3A) and activation of sPLA2 expression (Figure 3B) induced by SAA.  These 
findings are consistent with previous studies demonstrating cross-talk between 
the activities of both of these enzymes.  For instance, Kuwata et al. have shown 
that activation of sPLA2 by IL-1β or TNF-α requires the products produced by, 
and therefore activity of, cPLA2 in rat fibroblastic 3Y1 cells (195,235).  Likewise, 
cPLA2 activity was required for sPLA2 activation in both P388D macrophages 
(236)  and HEK293 cells (237).  Interestingly, sPLA2 has also been shown to be 
important for the activation of cPLA2. Addition of exogenous sPLA2 in sPLA2-
deficient MC3T3-E1 cells increased expression of cPLA2 (238) and sPLA2 
activates cPLA2 in rat glomerular mesangial cells (239).  The results reported 
here provide a new role for cPLA2 activity to impact the activation of sPLA2 in 
SMCs which has downstream consequences on cholesterol trafficking to the ER.   
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IL-1β promotes cholesterol trafficking to the ER 
IL-1β induced expression of sPLA2 mRNA (Figure 5A), consistent with 
results previously demonstrated in our laboratory (135).  As expected, activation 
of sPLA2 resulted in trafficking of cholesterol to the ER (Figure 5B) further 
supporting that activation of sPLA2 in SMCs results in cholesterol trafficking to 
the ER.  Many others have reported that TNF-α and IFN-γ activate sPLA2 
expression in various cell types (240–243).  However, some discrepancies in 
other cells type have been shown.  IFN-γ induced sPLA2 in human airway 
epithelial cells whereas TNF-α did not (244).  In addition, in human SMCs, TNF-α 
antagonized IFN-γ-mediated sPLA2 activation (245).  In neonatal rat aortic SMCs, 
sPLA2 expression was not induced by either TNF-α nor by IFN-γ (Figure 5A), 
further supporting cell type-dependency.  Consistent with the lack of sPLA2 
induction, cholesterol trafficking was unperturbed by either of these reagents 
(Figure 5B).  
SAA promotes SMC phenotype modulation 
Our studies determined that SAA treatment of SMCs led to a strong 
repression of SMC-specific marker genes of the contractile phenotype including:  
Acta2, Tagln, Myh11, Cnn1, and Smtn (Figure 8).  Western blotting experiments 
confirmed that repression of the Acta2 and Tagln genes resulted in less αSMA 
and SM22 protein present in SMCs treated with SAA (Figure 9). Additional 
studies demonstrated that SAA up-regulated SMC expression of inflammatory 
genes (Figure 14) including cytokines (Il1b, Il6, and Cxcl1) and inflammation-
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associated cell adhesion molecules (Vcam1 and Icam1).  Recombinant SAA-1 
repressed SMC-specific contractile markers and up-regulated inflammatory 
genes as well (Figure 17).  These data recapitulated the effects shown with the 
hybrid SAA molecule, supporting the notion that results demonstrated in 
experiments with hybrid SAA are physiologically relevant. 
This work builds upon previous studies in the laboratory, showing SAA-
mediated activation of inflammatory sPLA2 (135) and MMP9 (137) in SMCs. SAA 
promoted gene expression changes in vascular SMCs consistent with a change 
in phenotype from a contractile cell to an inflammatory one, supporting the work 
of others showing that SMCs switch to an inflammatory phenotype 
(32,96,104,105).  Importantly though, these studies demonstrated SAA as a 
novel mediator capable of impacting SMC phenotype in the context of the 
atherosclerotic lesion.  Modulation of SMC phenotype from the contractile state 
to an inflammatory phenotype represents a potentially pro-atherogenic function of 
SAA that is undocumented in the literature.   
Protein expression and/or secretion of the inflammatory molecules 
reported here are still not known, however it is interesting to consider their 
contribution to the well-documented inflammatory cycle that occurs during 
atherogenesis.  Vcam1 expression, up-regulated by 1-methyl-Trp in SMCs led to 
increased CD68 macrophage accumulation in developing plaque and ultimately 
an acceleration of atherosclerosis in Apoe-/- mice (246).  Furthermore, IL-1β 
contributes to macrophage recruitment to atherosclerotic plaques.  Inhibition 
102 
using an IL-1β targeting antibody reduced recruitment (247),  while inactivation of 
the IL-1 receptor antagonist increased plaque macrophage content (248).  IL-6 
production in response to TLR2 activation, mediated in part by p38 MAPK, 
promoted SMC migration in culture (87).  Interestingly, in a preliminary 
experiment using the specific p38 MAPK inhibitor SB203580, IL-6 up-regulation 
in response to SAA or in response to TLR2 activation by ligands did not appear 
to be mediated by p38 MAPK (data not shown).         
TLR2 activation promotes SMC phenotype modulation 
TLR2 agonists down-regulated SMC-specific contractile marker mRNA 
(Figure 10) and protein (Figure 11) expression.  In addition, TLR2-mediated 
activation of inflammatory genes was shown (Figure 14).  These results show 
that activation of TLR2, independent of SAA, promoted phenotype switching in 
SMCs from a contractile cell to an inflammatory one (32).  These results are 
significant in that SAA-mediated effects were highly dependent upon its state of 
association with lipids in that SAA associated with HDL was unable to promote 
SMC gene expression changes consistent with the described phenotype 
modulation (Figure 18). FSL-induced phenotype modulation was unaffected by 
HDL in these experiments, demonstrating the role of TLR2 in this process, 
regardless of the extracellular lipid environment.  The status of the association of 
SAA with lipid in atherosclerotic plaques is debatable.  Without a doubt, most of 
the SAA synthesized by the liver circulates in blood as an apolipoprotein 
associated with HDL (146), however evidence supports that it may be found lipid-
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free as well.  SAA cleavage products have been shown to be lipid-free in amyloid 
plaques (249).  Likewise, it has been suggested that extra-hepatic synthesis of 
SAA, e.g. SMCs, may be a source for lipid-free SAA (250–252).  Interestingly, a 
recent report demonstrated that SAA facilitates lesion development in Ldlr-/- mice 
and suggested that SAA expression by lesional macrophages contributed to the 
increased atherogenesis (129).  
It is clear that TLR2 is involved in the progression of atherosclerosis (162–
167).  Most recently, TLR2 was found to be necessary for P. gingivalis-mediated 
atherosclerosis in the Ldlr-/- model (253).  In this study, systemic IL-1β release led 
to increased macrophage activation within the vessel wall promoting foam cell 
formation and increasing their survival which resulted in increased plaque 
development.   The results shown in this dissertation contribute a new potential 
role for TLR2 to impact atherogenesis, beyond effects on macrophages, by 
promoting the phenotypic modulation of SMCs within the vessel wall.   
SAA-mediated SMC phenotype modulation is, at least partially, TLR2-dependent 
Knocking down TLR2 blocked SAA-mediated repression of SMC-specific 
contractile marker genes (Acta2, Myh11, and Cnn1) (Figure 13). In addition, 
SAA-mediated activation of Il6 and Cxcl1 was blocked when TLR2 was knocked 
down (Figure 15A).  On the other hand, activation of Vcam1 mediated by SAA 
occurred regardless of TLR2 knockdown, suggesting that SAA promotes an 
inflammatory SMC phenotype through both TLR2-dependent as well as TLR2-
independent mechanisms.  
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Interestingly, the abrogation of these effects was not complete under 
these conditions, i.e. there was still some repression or activation of these genes 
by SAA after TLR2 knockdown. Firstly, the knockdown of TLR2 was not 
complete.  Knockdown was considered successful when Tlr2 mRNA expression 
was reduced by ~75-90%, suggesting that some TLR2 could be present at the 
cell surface to signal in response to SAA.  Secondly, SAA (and the other TLR2 
agonists) activated expression of Tlr2 mRNA (Figure 12).  This response is 
consistent with previous reports by others that activation of TLR2 results in the 
up-regulation of its own mRNA expression (206).  In knockdown conditions, Tlr2 
mRNA was more highly expressed in the activated cells compared to untreated 
ones, further suggesting the availability of TLR2 to convey signals in response to 
SAA. 
It is also plausible that SAA signals through other receptors.  As previously 
discussed, many receptors for SAA have been reported in the literature (143–
148).  CD36 represents an interesting potential receptor for SAA to transduce 
SMC phenotype modulation.  In macrophages and liver Kϋpffer cells, SAA-
mediated production of cytokines was dependent upon CD36 (201).  
Interestingly, CD36 is a co-receptor for TLR2/6 signaling (254), but can also 
signal independently of TLR2 with similar downstream intracellular cascades 
involving NF-κB and MAPK activation (255).  The role of SR-BI is also of interest 
here.  Cai et al. showed that SAA is a functional ligand of SR-BI in Chinese 
hamster ovary cells irrespective of the lipid status of SAA (146).  Preliminary 
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results in our laboratory examined a role for SR-BI in SAA-mediated effects.  
Mmp9 mRNA expression, up-regulated by SAA, was blocked when SR-BI was 
knocked down via siRNA (data not shown), suggesting a role for SR-BI in that 
effect.  Interestingly, FSL-mediated activation of MMP9 was also blocked by SR-
BI knockdown, demonstrating that SR-BI is required for TLR2-mediated effects.  
To our knowledge, no existing reports suggest any functional cross-talk between 
these two receptors. 
Overall, our results show that SAA activates TLR2 to mediate SMC 
phenotype modulation.  Future studies could be directed at identifying the role of 
redundant SAA-receptors, such as CD36 or SR-BI, in the neonatal rat SMC 
culture system.  Furthermore, experiments using SMCs isolated from Tlr2-/- mice, 
in which the other receptors in question have been knocked down by siRNA or 
crossed with knockouts of these receptors, may help identify redundancies 
mediating SMC phenotype modulation by SAA.  Finally, it would be important to 
investigate the ability of SAA or TLR2 activation to modulate SMC phenotype in 
vivo atherosclerosis disease models.   
Myocardin down-regulation promotes switch from the contractile phenotype 
Acta2 promoter activity was down-regulated by SAA, FSL, or Pam (Figure 
19) demonstrating that the repression of SMC-specific contractile occurred at the 
level of transcription.  Myocardin is a critical transcription factor responsible for 
driving SRF/CArG-dependent transcription of SMC-specific contractile genes.  
These results demonstrate that Myocd mRNA and protein expression are down-
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regulated by SAA and additional TLR2 agonists (Figures 20 & 21).  These data 
show that repression of myocardin decreases promoter activity of SMC 
contractile genes, leading to their repression at the level of transcription.  
Exogenous addition of myocardin, via overexpression, blocked SAA-mediated 
repression of the Acta2 promoter (Figure 22A), as well as SAA- and FSL-
mediated repression of the Tagln promoter (Figure 22B).  Overexpression of the 
myocardin family members, MRTF-A and MRTF-B, also rescued repression of 
the Tagln promoter (Figure 23A). However, nuclear localization of MRTF-A, 
which determines its activity, was not enhanced in response to SAA in 
preliminary experiments (Figure 23B).  It is likely that that these transcription 
factors are not involved in SAA-/TLR2-mediated SMC phenotype modulation, but 
further experiments would be necessary to draw definitive conclusions.  Taken 
together, these data demonstrate that SAA-/TLR2-mediated SMC phenotype 
modulation is dependent upon myocardin repression, ultimately resulting in 
decreased promoter activity of contractile genes.  The results shown here 
provide a novel role for SAA and TLR2 signaling to repress myocardin 
expression in SMCs, leading to the down-regulation of SMC-specific contractile 
genes.   
Our results are consistent with the current understanding of myocardin 
and confirm studies demonstrating that loss of myocardin represses promoter 
activity of SMC-specific marker genes (29).  The role of myocardin in SAA-
/TLR2-mediated activation of inflammatory genes has not yet been explored.  
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Tang et al. showed that myocardin decreases p65-mediated target gene 
activation by interfering with p65-DNA binding (256).  Presumably, loss of 
myocardin would enhance p65-DNA binding, resulting in increased NF-κB activity 
and thus inflammatory cytokine production.  Conversely, silencing of MRTF-A, a 
closely related family member of myocardin, decreased NF-κB-dependent pro-
inflammatory transcription (257).  
Additionally, hnRNA expression of Myocd was repressed by SAA (Figure 
20B), suggesting that regulation of myocardin occurs transcriptionally.  Akt 
affects myocardin expression, in particular its transcription.  Abdalla et al. 
showed that Akt1 deficiency decreased myofibroblast myocardin expression in 
vivo (213).  On the other hand, Yang et al. showed that FoxO3a, a downstream 
target of Akt signaling, represses myocardin promoter activity (215), suggesting 
that Akt activation negatively impacts myocardin transcription.  FSL led to a rapid 
activation of Akt, as measured by phosphorylation at Ser473 (Figure 24).   
Repression of Myocd mRNA expression by FSL occurred even when Akt1 
activation was inhibited using the pharmacological inhibitor MK2206 (Figure 25).  
Taken together, these data demonstrate that SAA-/TLR2-mediated myocardin 
repression occurs independently of Akt.  Other means of myocardin control are 
possible and have been demonstrated in the literature.  STAT3 was recently 
demonstrated to negatively impact myocardin-induced expression of contractile 
genes in vascular SMCs (258).  In addition, knockdown of ten-eleven 
translocation-2  inhibited MYOCD mRNA expression in human SMCs (259).  
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Krϋppel-like factor 4 (Klf4) is also a negative regulator of myocardin expression 
(260).  In particular, an upstream Klf4-dependent repressor region in the MYOCD 
gene was demonstrated in human SMCs by Turner et al. (261).  To pursue the 
possible role of Klf4, its expression was studied in neonatal rat aortic SMCs 
treated with SAA and other agonists of TLR2.  Although Klf4 mRNA expression 
was up-regulated, knocking down Klf4 had no impact on myocardin repression in 
response to TLR2 activation (data not shown).  This suggests a Klf4-independent 
mechanism for TLR2-mediated SMC phenotype modulation.  
SMC phenotype modulation occurs independently of cholesterol trafficking to the 
ER 
Incorporation of [14C]oleic acid into [14C]cholesteryl ester increased in 
SMCs treated with either FSL or Pam (Figure 26A).  These data demonstrate 
that TLR2 activation, irrespective of SAA, mobilizes cholesterol, presumably via 
the same mechanism, from the plasma membrane to the ER.  To our knowledge 
a role for TLR2 in intracellular cholesterol trafficking has not been demonstrated.  
Loading SMCs with cholesterol was demonstrated to impact the 
contractile phenotype (262).  A series of experiments were performed to 
determine if SAA- and/or TLR2-mediated cholesterol trafficking impacted the 
changes in SMC gene expression.  Inhibition of cholesterol trafficking using the 
lysosome inhibitor, chloroquine, had no effect on the ability of SAA, FSL, or Pam 
to down-regulate SMC-specific contractile genes or to up-regulate inflammatory 
genes (Figure 26).  Similarly, SMC phenotype modulation still occurred when 
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cholesterol trafficking was blocked by exogenous addition of sphingomyelin 
(Figure 27).  Finally, removal or addition of cholesterol to SMC cultures had no 
effect on the down-regulation of SMC-specific contractile genes or on the up-
regulation of inflammatory genes (Figure 28).  Taken together, these data 
demonstrate that SMC gene expression changes due to SAA, FSL or Pam 
occurred regardless of cholesterol trafficking.   
Summary 
These studies showed that SAA mobilizes cholesterol from the plasma 
membrane to the ER and that this process is lysosome-, sPLA2-, cPLA2-, and 
sphingomyelinase-dependent.  In addition, SAA promoted gene expression 
changes resulting in the down-regulation of SMC-specific contractile markers and 
the activation of inflammatory genes, changes likely to induce a switch from the 
contractile to an inflammatory phenotype.  Loss of myocardin protein was shown 
to be critical for SAA-mediated down-regulated of the SMC-specific contractile 
genes. 
Activation of TLR2 mobilized cholesterol from the plasma membrane to 
the ER and promoted SMC gene expression changes consistent with SMC 
phenotype modulation.  These findings provide important novel effects of TLR2 
signaling in SMCs that may contribute to its ability to promote atherogenesis.  
Many SAA-mediated gene changes were found to be TLR2-dependent.  
Endogenous ligands capable of activating TLR2 during the chronic inflammation 
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associated with atherosclerosis are not well defined.  In light of these results, 
SAA could potentially represent such a ligand that impacts SMC function. 
The work presented here has identified novel roles for SAA and TLR2 
signaling to promote atherogenic changes in vascular SMCs (Figure 29).  
Blocking these processes may represent new therapeutic avenues to control 
development of atherosclerosis. 
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